

CITATION REPORT

List of articles citing

American College of Rheumatology 2008
recommendations for the use of nonbiologic and
biologic disease-modifying antirheumatic drugs in
rheumatoid arthritis

DOI: 10.1002/art.23721

Arthritis and Rheumatism, 2008, 59, 762-84.

Source: <https://exaly.com/paper-pdf/43431115/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1236	Adherence to Methotrexate therapy in Rheumatoid Arthritis. 2016 , 32, 413-7		3
1235	The familial nature of multiple sclerosis: age-corrected empiric recurrence risks for children and siblings of patients. 1988 , 38, 990-1		88
1234	Leflunomide for treating rheumatoid arthritis. 2003 , CD002047		24
1233	The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road. <i>Arthritis and Rheumatism</i> , 2008 , 59, 757-9		32
1232	Pay for performance in rheumatology: will we get the carrot or the stick?. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1203-6		2
1231	Reply. <i>Arthritis and Rheumatism</i> , 2008 , 61, 140-141		1
1230	Inclusion of glucocorticoids in recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: Comment on the article by Saag et al. <i>Arthritis and Rheumatism</i> , 2009 , 61, 141-2; author reply 141-2		1
1229	T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. 2008 , 10, R136		59
1228	Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations. 2008 , 10, 215		56
1227	Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. 2008 , 106, 778-87		25
1226	Indian Rheumatology Association consensus statement on the management of adults with rheumatoid arthritis. 2008 , 3, S1-S16		25
1225	Pharmacogenetics of etanercept in rheumatoid arthritis. 2008 , 9, 1011-5		16
1224	Mycobacterial disease in patients with rheumatic disease. 2008 , 4, 649-56		30
1223	Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis. 2009 , 1, 17-35		3
1222	TNF Inhibitor Use during the Perioperative Period. 2009 , 16, 175		
1221	The Efficacy and Safety of Leflunomide in the Treatment of Rheumatoid Arthritis. 2009 , 16, 71		
1220	Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. 2009 , 3, 335-44		83

1219	Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. 2009 , 4, e6242	58
1218	Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. 2009 , 15, 1556-61	217
1217	Discussion: DMARDs and biologic therapies in the management of inflammatory joint diseases. 2009 , 5, 291-9	6
1216	A Bayesian Approach to Therapy Selection in the Treatment of Refractory Rheumatoid Arthritis. 2009 , 38, 3406-3418	
1215	Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. 2009 , 36, 546-51	34
1214	Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. 2009 , 36, 2416-20	99
1213	Therapy: methotrexate guidelines: compromise to reach consensus. 2009 , 5, 186-7	2
1212	Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. 2009 , 36, 1611-7	52
1211	Safety of Anti-tumor necrosis factor (Anti-TNF) therapy in patients with chronic Hepatitis B. 2009 , 6, 89	1
1210	Infectious complications associated with monoclonal antibodies and related small molecules. 2009 , 22, 274-90, Table of Contents	79
1209	Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice. 2009 , 36, 1561-2	1
1208	Comparative overview of safety of the biologics in rheumatoid arthritis. 2009 , 82, 25-32	38
1207	Assessment and management of rheumatoid arthritis. 2009 , 82, 2-10	4
1206	Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. 2009 , 19, 652-656	6
1205	A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. 2009 , 19, 384-389	8
1204	Certolizumab pegol for rheumatoid arthritis: effective in combination with methotrexate or as monotherapy. 2009 , 4, 253-266	3
1203	Practical aspects of therapeutic intervention in rheumatoid arthritis. 2009 , 82, 39-41	5
1202	Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. 2009 , 19, 513-521	2

1201	Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists. 2009 , 15, 1700-1	17
1200	American College of Rheumatology recommendations for the treatment of RA: an issue of choices. 2009 , 5, 8-9	3
1199	Is there a role for everolimus in the treatment of RA?. 2009 , 5, 68-9	
1198	Rheumatoid arthritis: Guidelines for the management of RA: breadth versus depth. 2009 , 5, 302-3	2
1197	Therapeutic options for rheumatoid arthritis. 2009 , 10, 2095-106	24
1196	New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?. 2009 , 68, 767-9	12
1195	Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. 2009 , 36, 2435-42	51
1194	Recent Developments in the Treatment of Rheumatoid Arthritis. 2009 , 22, 65-74	3
1193	Systematic review and metaanalysis of patient self-report versus trained assessor joint counts in rheumatoid arthritis. 2009 , 36, 2635-41	50
1192	Assessing infection risk with biologic agents in RA: methodological challenges. 2009 , 5, 288-91	5
1191	Clinical practice guidelines and diagnostic uncertainty in the management of early rheumatoid arthritis. 2009 , 36, 863-4	2
1190	Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). 2009 , 7 Suppl 1, 332-9	219
1189	B-cell depletion in autoimmune diseases. Advances in autoimmunity. 2009 , 8, 585-90	20
1188	Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs. 2009 , 77, 1161-72	8
1187	Progression in early rheumatoid arthritis. 2009 , 23, 59-69	57
1186	Inflammatory bowel disease and hepatitis B and C. 2009 , 33, 1082-93	19
1185	Maladies inflammatoires chroniques intestinales et h�patites B et C. 2009 , 33, e1-e14	
1184	Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. <i>Arthritis and Rheumatism</i> , 2009 , 61, 300-4	69

1183	Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 745-54	26
1182	Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences. <i>Arthritis and Rheumatism</i> , 2009 , 61, 425-34	17
1181	Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2880-91	70
1180	Improved influenza and pneumococcal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1505-10	63
1179	Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3207-16	118
1178	Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3774-83	9
1177	Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. 2009 , 19, 652-6	10
1176	Expression of multidrug resistance-1 protein correlates with disease activity rather than the refractoriness to methotrexate therapy in rheumatoid arthritis. 2009 , 28, 427-33	15
1175	Managing the risks of IBD therapy. 2009 , 11, 509-17	5
1174	Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor. 2009 , 11, 229-36	6
1173	Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. 2009 , 29, 1287-91	22
1172	Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. 2009 , 161, 723-31	54
1171	Rheumatoid arthritis market. 2009 , 8, 693-4	30
1170	FAST4WARD: implications for the clinician. 2009 , 63, 986-8	1
1169	Anti-CD20 antibody rituximab in the treatment of rheumatoid arthritis. 2010 , 106, 13-21	20
1168	Cytokines as targets for anti-inflammatory agents. 2009 , 1182, 88-96	8
1167	[Infectious pulmonary complications of rheumatic diseases]. 2009 , 68, 658-64	2
1166	Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. 2009 , 68, 1680-5	145

1165	Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics. 2009 , 80, 693-703	95
1164	Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. 2009 , 68, 1100-4	410
1163	Improving pregnancy counseling for women with rheumatoid arthritis taking methotrexate. 2009 , 122, 998-1000	1
1162	[Biologics as first line therapy in the treatment of rheumatoid arthritis. A posture a favor]. 2009 , 5 Suppl 1, 22-7	
1161	[Not Available]. 2009 , 5, 143-6	8
1160	Cytokine biomarkers and the promise of personalized therapy in rheumatoid arthritis. 2009 , 5, 143-146	
1159	Tocilizumab: a review of its use in the management of rheumatoid arthritis. 2009 , 69, 609-32	114
1158	B cell depletion in early rheumatoid arthritis: a new concept in therapeutics. 2009 , 1173, 729-35	5
1157	Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?. 2009 , 11, 253	25
1156	Outcome measures in inflammatory rheumatic diseases. 2009 , 11, 244	33
1155	Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. 2009 , 26, 273-93	19
1154	Preventing and treating biologic-associated opportunistic infections. 2009 , 5, 405-10	50
1153	Interferon gamma for idiopathic pulmonary fibrosis. 2009 , 374, 180-2	8
1152	Treatment of rheumatoid arthritis: we are getting there. 2009 , 374, 178-80	27
1151	Prognostic factors in rheumatoid arthritis in the era of biologic agents. 2009 , 5, 491-6	20
1150	The Disease Activity Score and the EULAR response criteria. <i>Rheumatic Disease Clinics of North America</i> , 2009 , 35, 745-57, vii-viii	2.4 211
1149	RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. <i>Rheumatic Disease Clinics of North America</i> , 2009 , 35, 773-8, viii	2.4 81
1148	Monitoring methotrexate toxicity in juvenile idiopathic arthritis. 2009 , 36, 2813-8	17

1147	Early inflammatory arthritis versus rheumatoid arthritis. 2009 , 21, 118-23	14
1146	Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. 2009 , 21, 419-24	7
1145	Current world literature. 2009 , 21, 425-42	
1144	Infectious complications of biological therapy. 2009 , 21, 397-403	16
1143	Update on rheumatology: part 1. 2009 , 27, 286-96; quiz 297-8	1
1142	An elderly man with rheumatoid arthritis and dyspnea. 2009 , 135, 1090-1093	5
1141	2. How to Use Anti-rheumatoid Drugs Including Methotrexate (MTX). 2009 , 98, 2493-2499	
1140	Unmet needs in rheumatoid arthritis. 2009 , 82, 42-6	12
1139	Role and place of methotrexate in vasculitis management. 2009 , 4, 697-715	1
1138	CTLA-4Ig: uses and future directions. 2009 , 3, 132-42	6
1137	Strategies for treating rheumatoid arthritis: new guidelines from the ACR. 2009 , 4, 3-5	
1136	Biologic agents for rheumatoid arthritis: 2008 and beyond. 2009 , 32, S4-17; quiz S19-24	5
1135	Healthy lifestyle interventions in general practice Part 11: Lifestyle and arthritic conditions Rheumatoid arthritis. 2010 , 52, 176-183	1
1134	How and when to use DMARDs. 2010 , 35, 12-4	
1133	Observational cross-sectional study revealing less aggressive treatment in Japanese elderly than nonelderly patients with rheumatoid arthritis. 2010 , 16, 370-4	13
1132	Rheumatic manifestations of hepatitis. 2010 , 22, 91-6	16
1131	Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis. 2010 , 22, 316-20	20
1130	Current Opinion in Rheumatology. Current world literature. 2010 , 22, 456-70	

1129	Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. 2010 , 22, 494-9	30
1128	The A, B, Cs of viral hepatitis in the biologic era. 2010 , 22, 443-50	27
1127	Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. 2010 , 48, S83-9	25
1126	4) Antibody Therapy for Rheumatoid Arthritis.. 2010 , 99, 2177-2182	
1125	Viruses and arthritis: new challenges in diagnosis, therapy, and immunization. 2010 , 339, 549-56	8
1124	Rituximab for Rheumatoid Arthritis: A Meta-Analysis and Systematic Review. 2010 , 2, CMT.S5566	
1123	Successes achieved and challenges ahead in translating biomarkers into clinical applications. 2010 , 12, 243-53	22
1122	[How closely does rheumatology treatment follow the guidelines?: ambition and reality]. 2010 , 69, 318-26	8
1121	[Infectious complications of biologic therapy in patients with rheumatoid arthritis]. 2010 , 69, 879-88	1
1120	Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review. 2010 , 69, 337-44	60
1119	State-of-the-art: rheumatoid arthritis. 2010 , 69, 1898-906	215
1118	Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients' beliefs about the medicine. A prospective cohort study. 2010 , 30, 1441-8	60
1117	Les critères d'évaluation rapportés par le patient dans la polyarthrite rhumatoïde. 2010 , 77, 28-31	
1116	Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis. 2010 , 29, 33-8	11
1115	Development of a framework for reporting health service models for managing rheumatoid arthritis. 2010 , 29, 151-65	8
1114	Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy. 2010 , 29, 233-9	2
1113	Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. 2010 , 29, 495-500	50
1112	Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. 2010 , 29, 583-91	17

1111	Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. 2010 , 29, 1021-9	93
1110	MR imaging of atlantoaxial joint in early rheumatoid arthritis. 2010 , 115, 1111-20	15
1109	Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. 2010 , 55, 3207-17	24
1108	The risk of infections with biologic therapies for rheumatoid arthritis. 2010 , 39, 327-46	204
1107	Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. 2010 , 40, 147-63	30
1106	Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. 2010 , 30, 339-53	82
1105	[Pulmonary tuberculosis associated to adalimumab: a study of 3 cases]. 2010 , 46, 203-5	4
1104	Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor- β inhibitor. 2010 , 32, 1681-703	25
1103	Safety profile of abatacept in rheumatoid arthritis: a review. 2010 , 32, 1855-70	21
1102	Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. 2010 , 9, 574-82	36
1101	Pharmacotherapy: concepts of pathogenesis and emerging treatments. Challenges in clinical trial design in inflammatory arthritis. 2010 , 24, 457-61	1
1100	Pharmacotherapy: concepts of pathogenesis and emerging treatments. Optimising the strategy of care in early rheumatoid arthritis. 2010 , 24, 443-55	11
1099	Reducing methotrexate errors. 2010 , 31, 361-4	0
1098	Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate. 2010 , 77, 588-92	26
1097	Efficacy of methotrexate in ulcerative colitis: failure or promise. 2010 , 16, 1421-30	26
1096	Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. 2010 , 62, 730-4	23
1095	Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. 2010 , 62, 755-63	129
1094	Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. 2010 , 62, 857-64	122

1093	Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. 2010 , 62, 775-84	184
1092	Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?. 2010 , 62, 585-9	12
1091	Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. 2010 , 62, 1034-9	64
1090	Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease. 2010 , 62, 1095-102	17
1089	Rheumatologists' awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. 2010 , 62, 704-11	38
1088	American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2010 , 62, 1515-26	527
1087	Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2852-63	92
1086	Utilisation des thérapeutiques ciblées en monothérapie au cours de la polyarthrite rhumatoïde. 2010 , 77, 536-538	
1085	Managing inflammatory arthritides: Role of the nurse practitioner and physician assistant. 2010 , 22, 382-92	7
1084	Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. 2010 , 69, 143-51	35
1083	Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. 2010 , 40, 561-5	5
1082	New and emerging therapies for the treatment of rheumatoid arthritis. 2010 , 2, 35-43	7
1081	Management of Established Rheumatoid Arthritis. 2010 , 27-37	
1080	Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. 2010 , 2, 53-71	6
1079	Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence. 2010 , 16, 593-604	42
1078	Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. 2010 , 4, 263-78	64
1077	Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. 2010 , 16, 402-16	13
1076	[Management of elderly-onset rheumatoid arthritis]. 2010 , 33, 1-7	3

1075	Medical treatment of rheumatoid arthritis (I): Nonsteroidal anti-inflammatory drugs, disease modifying antirheumatic drugs and glucocorticoids. 2010 , 53, 871	2
1074	TNF-Inhibitors: are they carcinogenic?. 2010 , 2, 241-7	14
1073	Initiation of rheumatoid arthritis treatments and the risk of serious infections. 2010 , 49, 82-90	56
1072	In the clinic. Rheumatoid arthritis. 2010 , 153, ITC1-1-ITC1-15; quiz ITC1-16	27
1071	A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. 2010 , 49, 91-8	49
1070	A modified rheumatoid arthritis disease activity score without acute-phase reactants (mDAS28) for epidemiological research. 2010 , 37, 1607-14	12
1069	First-line DMARD choice in early rheumatoid arthritis--do prognostic factors play a role?. 2010 , 49, 1267-71	15
1068	Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis. 2010 , 44, 135-44	10
1067	Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study. 2010 , 39, 197-205	39
1066	Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. 2010 , 69, 671-6	80
1065	Leflunomide: a drug with a potential beyond rheumatology. 2010 , 2, 637-50	53
1064	Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. 2010 , 37, 723-9	14
1063	Patient-Reported Outcomes in Rheumatoid Arthritis: Why are They Important and How Should They Be Assessed?. 2010 , 25, 99-104	9
1062	Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial. 2010 , 37, 2469-74	12
1061	NICE guidance on rheumatoid arthritis: implications and challenges for rheumatologists. 2010 , 49, 619-20	5
1060	Improving the routine management of rheumatoid arthritis: the value of tight control. 2010 , 37, 1570-8	23
1059	New understanding and approaches to treatment in rheumatoid arthritis. 2010 , 94, 201-14	15
1058	Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. 2010 , 69, 380-6	193

1057	Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes. 2010 , 69, 941-2	9
1056	Safety of combination therapies in early rheumatoid arthritis: a systematic comparison between antirheumatic drugs and TNF inhibitors with methotrexate. 2010 , 5, 547-554	6
1055	Comparison of low-field dedicated extremity magnetic resonance imaging with articular ultrasonography in patients with rheumatoid arthritis. 2010 , 20, 556-560	19
1054	Vaccines and inflammatory bowel disease. 2010 , 28, 525-35	21
1053	Do we really need five TNF antagonists?. 2010 , 49, 1028-9	1
1052	Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. 2010 , 37, 1422-30	29
1051	Rheumatoid arthritis: Guidelines for RA therapy-avoiding hamartia. 2010 , 6, 505-6	3
1050	Rheumatologic manifestations of sarcoidosis. 2010 , 31, 463-73	60
1049	[Does early treatment of Rheumatoid Arthritis lead to a better long-term prognosis?]. 2010 , 6, 106-10	2
1048	Emerging trends in diagnosis and treatment of rheumatoid arthritis. 2010 , 37, 779-92, vii	26
1047	Surveillance for and prevention of nonrheumatologic diseases in the patient with a rheumatologic diagnosis. 2010 , 37, 793-804, vii	
1046	Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. 2010 , 31, 565-88	24
1045	Tumor necrosis factor blockade and the risk of viral infection. 2010 , 6, 165-74	113
1044	¹ H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. 2010 , 9, 4545-53	75
1043	Conservative treatments for rheumatoid arthritis in the foot and ankle. 2010 , 27, 193-207	3
1042	Secondary immunodeficiencies, including HIV infection. 2010 , 125, S195-203	119
1041	Fatigue in systemic lupus erythematosus and rheumatoid arthritis. 2010 , 2, 384-92	21
1040	New drugs for rheumatoid arthritis: The industry point of view. 2010 , 6, 3-4	

1039 New drugs for rheumatoid arthritis: The industry point of view. **2010**, 6, 3-4

1038 Does early treatment of Rheumatoid Arthritis lead to a better long-term prognosis?. **2010**, 6, 106-110

1037 Diagnóstico de supuesto cáncer pulmonar asociado al uso de metotrexato. **2010**, 13, 92-94

1036 Pulmonary Tuberculosis Associated to Adalimumab: a Study of 3 Cases. **2010**, 46, 203-205

0

1035 EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. **2010**, 69, 964-75

1210

1034 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. **2010**, 36, 1185-206

360

1033 The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. **2010**, 69, 1589-95

117

1032 A safety assessment of tumor necrosis factor antagonists during pregnancy. **2010**, 9, 421-9

21

1031 The safety profile of biologic therapies for juvenile idiopathic arthritis. **2010**, 6, 561-71

51

1030 [Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: effectiveness comparative study]. **2010**, 134, 665-70

5

1029 Pharmacology of glucocorticoids in rheumatoid arthritis. **2010**, 10, 302-7

31

1028 Agreement between erythrocyte sedimentation rate and C-reactive protein in hospital practice. **2010**, 123, 863.e7-13

34

1027 Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. **2010**, 13, 33-41

19

1026 Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. **2010**, 13, 12-26

17

1025 Rheumatoid arthritis. **2010**, 376, 1094-108

2155

1024 Management of Rheumatoid Arthritis. **2010**, 17-26

1023 Objectified assessment for effective disease management in rheumatoid arthritis: a little known secret. **2010**, 5, 1-2

1022 Practising computer-aided objectified outcome-driven targeted treatment of rheumatoid arthritis in a resource constrained country: results from a single rheumatology clinic. **2010**, 5, 3-10

2

1021	Certolizumab pegol: a new biologic targeting rheumatoid arthritis. 2010 , 6, 855-66	15
1020	The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. 2010 , 12, R35	44
1019	Treating rheumatoid arthritis to target: recommendations of an international task force. 2010 , 69, 631-7	1300
1018	Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications?. 2010 , 49, 341-7	103
1017	Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor- α antagonist therapy. 2010 , 14, 367-73	25
1016	Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital. 2010 , 39, 19-25	9
1015	Anti-tumor necrosis factor therapy in rheumatoid arthritis patients with a history of deep prosthetic joint infection: a report of four cases. 2011 , 21, 542-547	
1014	Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients. 2011 , 21, 375-380	20
1013	Efficacy and safety of single-dose mizoribine for patients with rheumatoid arthritis: results at 6 months after switching from a multiple-dose regimen without a change in total daily dose. 2011 , 21, 158-163	3
1012	Understanding emerging treatment paradigms in rheumatoid arthritis. 2011 , 13 Suppl 1, S3	42
1011	Advances in rheumatology: new targeted therapeutics. 2011 , 13 Suppl 1, S5	130
1010	Liver involvement in subjects with rheumatic disease. 2011 , 13, 226	43
1009	Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. 2011 , 21, 621-627	60
1008	Induction of clinical remission with adalimumab-methotrexate combination therapy in a patient with rheumatoid arthritis and concomitant hepatitis C virus infection. 2011 , 21, 696-700	2
1007	Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. 2011 , 40, 183-91	7
1006	Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. 2011 , 70, 39-46	199
1005	How does one manage patients with rheumatoid arthritis and positive serology to hepatitis B, hepatitis C, human immunodeficiency virus?. 2011 , 7, 203-207	1
1004	Chronische Polyarthritis. 2011 , 2, e167-e170	

1003 Biologikatherapie in der Rheumatologie. **2011**, 2, e164-e166

1002 Chinese herbal medicines versus disease modifying antirheumatic drugs for management of rheumatoid arthritis: A systematic review. **2011**, 3, e219-e231 9

1001 [How does one manage patients with rheumatoid arthritis and positive serology to hepatitis B, hepatitis C, human immunodeficiency virus?]. **2011**, 7, 203-7 6

1000 [Vaccines and chemo-prophylaxis in rhemautoid arthritis: is a vaccine calendar necessary?]. **2011**, 7, 412-6 10

999 [Glucocorticoids in rheumatoid arthritis: almost always or hardly ever?]. **2011**, 7, 407-11 1

998 Vaccines and Chemo-prophylaxis in Rheumatoid Arthritis: Is a Vaccine Calendar Necessary?. **2011**, 7, 412-416 1

997 Glucocorticoids in Rheumatoid Arthritis: Almost Always or Hardly Ever?. **2011**, 7, 407-411

996 Inhibidor del receptor de la interleucina-6 en el tratamiento de la artritis reumatoide: seguridad y dosificaci3n del tocilizumab. **2011**, 12, 57-60

995 Hepatobiliary manifestations of gastrointestinal and nutritional disorders. **2011**, 15, 89-110 4

994 Autoimmune Diseases. **2011**, 1

993 The impact of biologic response modifiers on hepatitis B virus infection. **2011**, 11, 533-44 20

992 Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement. **2011**, 13, R189 21

991 The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. **2011**, 13, R174 76

990 Integrated safety in tocilizumab clinical trials. **2011**, 13, R141 224

989 Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-3nhibitors. **2011**, 13, R25 67

988 Reconocer y tratar la artritis reumatoide. **2011**, 29, 24-29

987 Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. **2011**, 124, e1-18 5

986 Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO. **2011**, 22, 576-81 5

985	Comparison between DAS28, CDAI and HAQ-DI as tools to monitor early rheumatoid arthritis patients in eastern India. 2011 , 6, 116-122	10
984	Safety of biologic therapy in rheumatoid arthritis. 2011 , 7, 639-52	50
983	PHARMACOLOGY AND DRUG THERAPY. 2011 , 71-126	18
982	Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis. 2011 , 41, 492-6	10
981	The microbiome and rheumatoid arthritis. 2011 , 7, 569-78	303
980	Certolizumab in the long-term treatment of rheumatoid arthritis. 2011 , 3, 63-71	1
979	Uso de terapias biológicas no tratamento da artrite reumatoide: comparação entre as principais recomendações mundiais e a brasileira. 2011 , 51, 225-230	1
978	Management of Rheumatoid Arthritis: Consensus Recommendations From the Turkish League Against Rheumatism. 2011 , 26, 273-294	11
977	Consenso da Sociedade Brasileira de Reumatologia 2011 para o diagnóstico e avaliação inicial da artrite reumatoide. 2011 , 51, 207-219	15
976	Assessment of disease activity and treatment outcomes in rheumatoid arthritis. 2011 , 17, S09-13	24
975	Investigation on Brazilian clinical practices in rheumatoid arthritis: the Brazilian rheumatoid arthritis clinical practices investigation--BRACTICE. 2011 , 17, S1-10	2
974	Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design. 2011 , 38, 2095-104	8
973	Treatment strategies in recent onset rheumatoid arthritis. 2011 , 23, 241-4	6
972	Remission: a realistic goal in rheumatoid arthritis?. 2011 , 6, 643-647	3
971	Recognizing and managing rheumatoid arthritis. 2011 , 41, 34-9; quiz 39-40	
970	Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. 2011 , 38, 990-6	38
969	Suppression of Erosive Arthritis by NF- κ B Inhibitors. 2011 , 7, 275-281	2
968	Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. 2011 , 171, 657-67	8

967	Building a departmental quality program: a patient-based and provider-led approach. 2011 , 86, 314-20	10
966	Advances in the development and application of biological therapies for rheumatoid arthritis: review of the latest clinical evidence. 2011 , 1, 557-573	
965	Biologic monotherapy for the treatment of rheumatoid arthritis. 2011 , 1, 1291-1300	3
964	Certolizumab pegol for the treatment of rheumatoid arthritis. 2011 , 8, 391-402	
963	[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 10. Hydroxychloroquine]. 2011 , 100, 2960-5	2
962	[Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors]. 2011 , 100, 2966-71	
961	Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. 2011 , 71, 7-19	22
960	Anti-inflammatory therapeutics for the treatment of atherosclerosis. 2011 , 10, 365-76	197
959	Drug monitoring in systemic lupus erythematosus: a systematic review. 2011 , 40, 559-75	9
958	Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. 2011 , 41, 81-9	33
957	Methods of formal consensus in classification/diagnostic criteria and guideline development. 2011 , 41, 95-105	204
956	TNF alpha antagonist therapy and safety monitoring. 2011 , 78 Suppl 1, 15-185	54
955	Pericarditis induced by prophylactic administration of isoniazid in a patient with rheumatoid arthritis. 2011 , 78, 99-100	1
954	Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. 2011 , 78, 100-1	35
953	Using targeted therapies alone for rheumatoid arthritis. 2011 , 78, 1-3	1
952	Cytomegalovirus infection in a patient with rheumatoid arthritis on low-dose methotrexate. 2011 , 78, 421-2	
951	Serum Dkk-1 levels of DISH patients are not different from healthy controls. 2011 , 78, 422-3	18
950	Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. 2011 , 33, 679-707	185

949	Inhibiting effects of Leflunomide metabolite on overexpression of CD147, MMP-2 and MMP-9 in PMA differentiated THP-1 cells. 2011 , 670, 304-10	16
948	In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. 2011 , 43, 41-9	23
947	Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines. 2011 , 1813, 2165-75	63
946	The use of conventional disease-modifying anti-rheumatic drugs in established RA. 2011 , 25, 523-33	12
945	Rheumatoid arthritis in 2011: an editorial. 2011 , 25, 435-46	1
944	Established rheumatoid arthritis: rationale for best practice: physicians' perspective of how to realise tight control in clinical practice. 2011 , 25, 509-21	14
943	Immune modulation of rheumatoid arthritis. 2011 , 25, 873-89	6
942	Biologicals for rheumatoid arthritis. 2011 , 343, d4027	14
941	Treating early rheumatoid arthritis intensively: current UK practice does not reflect guidelines. 2011 , 30, 103-6	8
940	Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. 2011 , 30, 303-12	29
939	Tuberculosis and anti-TNF treatment: experience of a central London hospital. 2011 , 30, 399-401	23
938	A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy. 2011 , 11, 155-61	12
937	Péricardite induite par l'administration prophylactique d'isoniazide chez un patient atteint de polyarthrite rhumatoïde. 2011 , 78, 191-192	
936	Infection à cytomégalo virus chez un patient atteint de polyarthrite rhumatoïde et traité par méthotrexate à faible dose. 2011 , 78, 393-394	1
935	Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases. 2011 , 11, 304	29
934	Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. 2011 , 63, 53-7	39
933	Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. 2011 , 63, 65-78	62
932	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. 2011 , 63, 465-82	531

931	Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. 2011 , 63, 1150-8	221
930	Reply. 2011 , 63, 1355-1356	
929	Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics. 2011 , 63, 1238-46	55
928	Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. 2011 , 63, 1680-90	61
927	Conventional disease-modifying antirheumatic drugs to treat rheumatoid arthritis. 2011 , 72, 657-663	
926	Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1479-85	111
925	Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis). <i>Arthritis and Rheumatism</i> , 2011 , 63, 1804-11	67
924	Quality measurement and improvement in rheumatology: rheumatoid arthritis as a case study. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3649-60	29
923	Inhibitory effects of hybrid liposomes on the growth of synoviocyte causing rheumatoid arthritis. 2011 , 21, 207-10	4
922	Évaluation de la fibrose hépatique par élastométrie chez les patients atteints de polyarthrite rhumatoïde traités par méthotrexate. 2011 , 78, 47-51	
921	Synovite villonodulaire pigmentée de la première articulation métatarsophalangienne. 2011 , 78, 394-395	
920	Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. 2011 , 38, 1585-92	68
919	Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. 2011 , 183, 675-8	84
918	Initiation of tumor necrosis factor- α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. 2011 , 306, 2331-9	256
917	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. 2011 , 27, 315-25	12
916	A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B. 2011 , 21, 701-705	18
915	The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis. 2011 , 10, 715-26	13
914	Abatacept: a biologic immune modulator for rheumatoid arthritis. 2011 , 11, 1113-29	7

913	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs: multicenter, double-blind, parallel-group trial. 2011 , 21, 458-468	21
912	The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. 2011 , 70, 1401-6	77
911	Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. 2011 , 50, 2223-32	42
910	A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. 2011 , 3, 81ra35	172
909	Levels of plasma fibrinogen are elevated in well-controlled rheumatoid arthritis. 2011 , 50, 1458-65	28
908	Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. 2011 , 70, 299-304	21
907	An observational study of tocilizumab and TNF- α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. 2011 , 50, 2093-9	20
906	Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality. 2011 , 50, 366-72	26
905	Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN). 2011 , 50, 926-31	49
904	Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice. 2011 , 125, 23-7	16
903	Gold sodium thiomalate for the treatment of rheumatoid arthritis in a patient with hepatitis B. 2011 , 45, e23	1
902	Evaluating treatment strategies in patients with early rheumatoid arthritis: merging modeling theory with clinical practice. 2011 , 38, 1538-40	0
901	Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. 2011 , 70, 2103-10	16
900	Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis. 2011 , 3, 133-49	14
899	Immunology: Prevention of infections in patients with autoimmune diseases. 2011 , 7, 198-200	10
898	TNF- α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. 2011 , 90, 139-145	61
897	Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis. 2011 , 38, 2141-9	16
896	Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. 2011 , 70, 935-42	180

895	The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. 2011 , 21, 444-448	14
894	Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. 2011 , 21, 469-475	83
893	Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. 2011 , 4, 539-58	30
892	The updated guidelines on the use of rituximab in rheumatoid arthritis. 2011 , 50, 2153-4	1
891	Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007. 2011 , 40, 16-21	16
890	Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort. 2011 , 38, 2342-5	13
889	Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study. 2011 , 38, 1875-83	2
888	A clinician's critique of rheumatoid arthritis health economic models. 2011 , 50 Suppl 4, iv48-iv52	4
887	Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. 2011 , 38, 1234-43	36
886	Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. 2011 , 305, 480-6	101
885	[Diagnostic studies in new onset symmetrical polyarthritis]. 2011 , 100, 44-6	
884	Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis. 2011 , 3, 97-105	
883	Diagnostic Value of Autoantibodies Against Citrullinated Peptide Antigens in Rheumatoid Arthritis: Comparison of Different Commercial Kits. 2011 , 26, 13-18	5
882	Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. 2012 , 51 Suppl 5, v22-30	61
881	The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. 2012 , 44, 665-71	41
880	Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. 2012 , 5, 27-42	47
879	Potential of optical spectral transmission measurements for joint inflammation measurements in rheumatoid arthritis patients. 2012 , 17, 081420	11
878	Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. 2012 , 39, 1583-602	104

877	Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. 2012 , 39, 1559-82	169
876	The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. 2012 , 51 Suppl 6, vi16-20	29
875	Placebo-controlled trials, ethics, and the goals of comparative effectiveness research: comment on "lack of head-to-head trials and fair control arms". 2012 , 172, 244-5	5
874	Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisals. 2012 , 51, 24-31	21
873	Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. 2012 , 71, 504-10	85
872	Management of rheumatoid arthritis 2012: a Canadian state of the art. 2012 , 39, 1497-9	
871	Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort. 2012 , 51, 1648-54	12
870	Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. 2012 , 39, 720-7	159
869	Current treatments of rheumatoid arthritis: from the 'NinJa' registry. 2012 , 8, 455-65	37
868	Safety of biologics in rheumatoid arthritis. 2012 , 7, 425-451	5
867	Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. 2012 , 71, 1820-6	45
866	Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. 2012 , 22, 209-215	10
865	Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. 2012 , 22, 844-848	27
864	The importance of patient participation in measuring rheumatoid arthritis flares. 2012 , 71, 1107-9	20
863	Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. 2012 , 51, 2120-30	80
862	Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naïve patients with early RA. 2012 , 51, 670-8	12
861	Level of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data. 2012 , 71, 386-9	42
860	Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?. 2012 , 71, 1942-9	50

859	Characterization of patients with arthritis referred for gold therapy in the era of biologics. 2012 , 39, 716-9	4
858	Do dynamic strengthening and aerobic capacity exercises reduce pain and improve functional outcomes and strength in people with established rheumatoid arthritis?. 2012 , 92, 1251-7	8
857	Risk of orthopedic surgical site infections in patients with rheumatoid arthritis treated with antitumor necrosis factor alfa therapy. 2012 , 2012, 369565	4
856	Lack of head-to-head trials and fair control arms: randomized controlled trials of biologic treatment for rheumatoid arthritis. 2012 , 172, 237-44	62
855	PROMs: a novel approach to arthritis self-management. 2012 , 21, 601-2, 605-7	13
854	When is switching warranted among biologic therapies in rheumatoid arthritis?. 2012 , 12, 319-33	29
853	Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate. 2012 , 22, 100-108	6
852	Rheumatoid arthritis: new treatments, better outcomes. 2012 , 37, 16-22; quiz 23	9
851	Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. 2012 , 27, 192-9	51
850	Pulmonary Infections in the Era of Biological Agents. 2012 , 8, 327-341	
849	(1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis. 2012 , 4, 165-171	55
848	Rapid diagnosis of Mycobacterium tuberculosis infection in children using interferon-gamma release assays (IGRAs). 2012 , 33, 217-26	9
847	The safety of anti-TNF therapy in patients with hepatitis B and C virus infection. 2012 , 7, 191-196	1
846	Acute myeloid leukemia developing in patients with autoimmune diseases. 2012 , 97, 805-17	50
845	Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. 2012 , 156, 743-5	59
844	The role of tocilizumab monotherapy in the management of rheumatoid arthritis: a review. 2012 , 7, 9-19	3
843	A public health approach to addressing arthritis in older adults: the most common cause of disability. 2012 , 102, 426-33	95
842	Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al. 2012 , 64, 1622-3; author reply 1623-4	4

841	Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor- β biologics by rheumatoid arthritis patients. 2012 , 42, 223-33	12
840	The status of fostamatinib in the treatment of rheumatoid arthritis. 2012 , 8, 609-15	8
839	Assessing the safety of biologic agents in patients with rheumatoid arthritis. 2012 , 51 Suppl 5, v38-47	99
838	Rheumatoid arthritis disease measurement: a new old idea. 2012 , 51 Suppl 6, vi21-7	29
837	Initial management of rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012 , 38, 311-252.4	15
836	Design of Clinical Development Programs. 2012 , 571-593	
835	Common anti-infective prophylaxis and vaccinations in autoimmune inflammatory rheumatic diseases. 2012 , 7, 21-28	2
834	American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. 2012 , 64, 797-808	863
833	Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. 2012 , 64, 1649-56	53
832	Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. 2012 , 31, 1169-75	52
831	What RA patients expect of their treatment--discussion over the result of our survey. 2012 , 31, 1559-66	8
830	Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience. 2012 , 31, 1663-9	18
829	The perioperative use of biologic agents in patients with rheumatoid arthritis. 2012 , 12, 164-8	11
828	Adverse drug reactions caused by methotrexate in Saudi population. 2012 , 20, 301-5	6
827	Dalle immunodeficienze alle malattie reumatologiche. 2012 , 13, 72-76	
826	Methotrexate safety improvement in nursing home residents. 2012 , 13, 69-74	9
825	Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0. 2012 , 8, 189-94	22
824	Satisfaction and attitudes toward therapy in patients with rheumatoid arthritis. 2012 , 22, 376-381	6

823	Tuberculosis after anti-TNF therapy: a continuous learning process. 2012 , 41, 401-3	3
822	Cardiovascular safety of biologic therapies for the treatment of RA. 2011 , 8, 13-21	33
821	Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection. 2012 , 4, 35-40	7
820	Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. 2012 , 28, 569-80	24
819	[Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm]. 2012 , 33, 4-12	8
818	Itraconazole: its possible role in inhibiting angiogenesis in rheumatoid arthritis. 2012 , 79, 313-4	8
817	Biosimilars in rheumatology; the new kid in the block: Panacea or pandoras box?. 2012 , 7, 67-68	
816	Advances in the treatment of inflammatory arthritis. 2012 , 26, 251-61	33
815	Reply. 2012 , 64, 1623-1624	
814	American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: comment on the article by Singh et al. 2012 , 64, 1622	8
813	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2824-35	271
812	2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. 2012 , 64, 1447-61	507
811	Overview of safety of non-biologic and biologic DMARDs. 2012 , 51 Suppl 6, vi37-43	86
810	Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. 2012 , 367, 508-19	658
809	Time trends in medication use and expenditures in older patients with rheumatoid arthritis. 2012 , 125, 937.e9-15	20
808	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. 2012 , 6, 116-31	13
807	A case of pancytopenia with signs of pulmonary fibrosis and liver cirrhosis secondary to low-dose methotrexate therapy in a patient with rheumatoid arthritis. 2012 , 3, 53-56	0
806	Patient Survival and Safety With Biologic Therapy. Results of the Mexican National Registry Biobadamex 1.0. 2012 , 8, 189-194	

805	Lupus éythémateux systéique induit par l'isoniazide. 2012 , 52, 462-464		0
804	My treatment approach to rheumatoid arthritis. 2012 , 87, 659-73		73
803	Arthritis and Musculoskeletal Conditions. 2012 ,		
802	2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. 2012 , 64, 1431-46		1061
801	Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. 2012 , 29, 664-74		71
800	Disease activity assessment and patient-reported outcomes in patients with early rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012 , 38, 299-310	2.4	5
799	An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy. 2012 , 32, 2725-9		6
798	Cost utility of tumour necrosis factor-é inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model. 2012 , 30, 575-93		22
797	Biologics-based therapy for the treatment of rheumatoid arthritis. 2012 , 91, 30-43		126
796	The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritis. 2012 , 12, 167		15
795	Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. 2012 , 14, R30		58
794	Laser in situ keratomileusis in patients with collagen vascular disease: a review of the literature. 2012 , 6, 1827-37		11
793	Rheumatoid Arthritis. 2012 , 1681-1689		2
792	Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis. 2012 , 4, 9-19		2
791	Comparison Korean National Health Insurance Reimbursement and Other Guidelines for TNF-é Blocker in Rheumatoid Arthritis. 2012 , 19, 334		5
790	Immunosuppressing Drugs Including Corticosteroids. 2012 , 159-165		1
789	Goals for rheumatoid arthritis: treating to target or treating to prevent?. 2012 , 4, 81-86		2
788	Total knee arthroplasty in rheumatoid arthritis. 2012 , 24, 1-6		47

787	Survey of a community-based infusion program for Australian patients with rheumatoid arthritis requiring treatment with tocilizumab: patient characteristics and drivers of patient satisfaction and patient-perceived benefits and concerns. 2012 , 6, 275-83	2
786	New concepts in systemic rheumatic diseases that are registered as rare diseases in Korea. 2012 , 55, 259	1
785	Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis. 2012 , 21, 666-9	10
784	Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. 2012 , 18, 1057-63	38
783	Management of rheumatic disease with comorbid HBV or HCV infection. 2012 , 8, 348-57	56
782	Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road. 2012 , 64, 648-51	8
781	2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. 2012 , 64, 625-39	1199
780	Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. 2012 , 51 Suppl 5, v31-7	23
779	American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. 2012 , 64, 465-74	1870
778	The Christchurch earthquake--providing a rheumatology service during a natural disaster. 2012 , 31, 723-5	3
777	Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. 2012 , 34, 457-67	21
776	Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. 2012 , 34, 788-802.e3	99
775	Abatacept therapy and safety management. 2012 , 79 Suppl 1, 3-84	26
774	Biologics in oral medicine: principles of use and practical considerations. 2012 , 18, 525-36	14
773	Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. 2012 , 15, 188-96	27
772	Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients. 2012 , 15, 315-21	9
771	A questionnaire survey of patient experience with the Rheumatology Monitoring Clinic in Singapore. 2012 , 15, 390-8	10
770	Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B. 2012 , 42, 523-31	

769	Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. 2012 , 64, 184-9	46
768	Influence of discipline of provider and model of care on an arthritis educational intervention in primary care. 2012 , 64, 424-33	3
767	Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. <i>Arthritis and Rheumatism</i> , 2012 , 64, 21-32	46
766	Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. <i>Arthritis and Rheumatism</i> , 2012 , 64, 630-8	55
765	High incidence of intolerance to tuberculosis chemoprophylaxis. 2012 , 32, 33-7	16
764	Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. 2012 , 32, 5-13	30
763	Chronic noninfectious uveitis associated with Vogt-Koyanagi-Harada disease treated with low-dose weekly systemic methotrexate. 2012 , 56, 104-6	13
762	Comparable efficacy of standardized Ayurveda formulation and hydroxychloroquine sulfate (HCQS) in the treatment of rheumatoid arthritis (RA): a randomized investigator-blind controlled study. 2012 , 31, 259-69	31
761	Is continuation of anti-tumor necrosis factor- α therapy a safe option for patients who have developed pulmonary mycobacterial infection? : Case presentation and literature review. 2012 , 31, 203-10	12
760	Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. 2013 , 22, 807-23	4
759	Biologics in oral medicine: Sjogren syndrome. 2013 , 19, 121-7	8
758	Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey. 2013 , 15, R43	15
757	Tools for monitoring remission in rheumatoid arthritis: any will do, let's just pick one and start measuring. 2013 , 15, 104	3
756	Update on the treatment of juvenile idiopathic arthritis. 2013 , 13, 337-46	25
755	[Screening investigations during intensified immunosuppression in children and adolescents. Part 1]. 2013 , 72, 814-21	5
754	Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2013 , 14, 13	2.8 35
753	Management of hip involvement in ankylosing spondylitis. 2013 , 32, 1115-20	24
752	Prophylaxis for latent tuberculosis infection prior to anti-tumor necrosis factor therapy in low-risk elderly patients with rheumatoid arthritis: a decision analysis. 2013 , 65, 1722-31	6

751	Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting. 2013 , 30, 517-27	13
750	Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. 2013 , 40, 403-10	49
749	Effects of dialysis on the pharmacokinetics of salazosulfapyridine. 2013 , 33, 535-9	2
748	[Comorbidity of rheumatic and hepatic diseases]. 2013 , 72, 547-54	1
747	Periprosthetic joint infection in patients with inflammatory joint disease: a review of risk factors and current approaches to diagnosis and management. 2013 , 9, 183-94	17
746	Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. 2013 , 12, 1076-84	48
745	Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. 2013 , 126, 1089-98	58
744	Acute- or subacute-onset lung complications in treating patients with rheumatoid arthritis. 2013 , 64, 200-7	4
743	Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. 2013 , 166, 199-207.e15	276
742	Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study. 2013 , 43, 55-62	27
741	[Glucocorticoids and... infections, doping, surgery, sexuality]. 2013 , 34, 269-78	2
740	Liver abnormalities in the immunosuppressed. 2013 , 27, 597-618	1
739	Tolérance des biothérapies : élaboration et validation d'un questionnaire évaluant les compétences d'auto-gestion et de sécurité du patient : le questionnaire BioSecure. Une initiative de la Société française de rhumatologie, section Éducation thérapeutique. 2013 , 80, 479-485	1
738	Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. <i>Arthritis and Rheumatism</i> , 2013 , 65, 3194-201	131
737	Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. 2013 , 84, 918-21	74
736	[Combination of biologics : where do we stand?]. 2013 , 72, 878-84	
735	Safety evaluation of leflunomide in rheumatoid arthritis. 2013 , 12, 581-8	30
734	Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease. 2013 , 54, 1235-41	5

733	Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. 2013 , 23, 709-715	24
732	Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures. 2013 , 84, 495-501	28
731	Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. 2013 , 23, 430-439	43
730	Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. 2013 , 72, 1897-904	96
729	Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. 2013 , 88, 83-105	118
728	Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles. 2013 , 7, 50-7	181
727	Rheumatic Disease. 2013 , 1415-1440	
726	Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis. 2013 , 698, 429-34	17
725	Prospective study of posttraumatic stress disorder and disease activity outcomes in US veterans with rheumatoid arthritis. 2013 , 65, 227-34	37
724	Increasing pneumococcal vaccination for immunosuppressed patients: a cluster quality improvement trial. <i>Arthritis and Rheumatism</i> , 2013 , 65, 39-47	40
723	A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis. 2013 , 53, 501-15	12
722	Diagnosis of early-stage rheumatoid arthritis: usefulness of unenhanced and gadolinium-enhanced MR images at 3 T. 2013 , 37, 348-53	10
721	Estudo clínico e laboratorial de pacientes com artrite reumatoide diagnosticados em serviços de reumatologia em Cascavel, PR, Brasil. 2013 , 53, 61-65	
720	A systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritis. 2013 , 53, 501-515	1
719	Diretrizes para o diagnóstico da artrite reumatoide. 2013 , 53, 141-157	10
718	PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis. 2013 , 43, 1-9	55
717	Baseline laboratory test abnormalities are common in early arthritis but rarely contraindicate methotrexate: study of three cohorts (ESPOIR, VERA, and Brittany). 2013 , 42, 474-81	11
716	Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. 2013 , 43, 48-54	31

715	Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. 2013 , 46, 65-7	19
714	Clinical and laboratory features of patients with rheumatoid arthritis diagnosed at rheumatology services in the Brazilian municipality of Cascavel, PR, Brazil. 2013 , 53, 57-65	3
713	Guidelines for the diagnosis of rheumatoid arthritis. 2013 , 53, 141-157	2
712	Safety of biologics: elaboration and validation of a questionnaire assessing patients' self-care safety skills: the BioSecure questionnaire. An initiative of the French Rheumatology Society Therapeutic Education section. 2013 , 80, 471-6	22
711	Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?. 2013 , 15, 295	61
710	Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. 2013 , 143, 814-824	195
709	Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009. 2013 , 65, 1529-33	30
708	Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. 2013 , 69, 377-83	41
707	Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. 2013 , 65, 854-61	62
706	Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. 2013 , 381, 451-60	472
705	Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV. 2013 , 15, 319	8
704	Review article: prescribing medications in patients with cirrhosis - a practical guide. 2013 , 37, 1132-56	124
703	Emerging anti-inflammatory drugs for atherosclerosis. 2013 , 18, 193-205	29
702	Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. 2013 , 5, 265-99	48
701	Hepatotoxicity of Immunosuppressive Drugs. 2013 , 569-591	7
700	Association of hepatitis B with antirheumatic drugs: a case-control study. 2013 , 23, 694-704	24
699	Same-day or historical ESR for disease activity score measurement: does it matter?. 2013 , 32, 261-5	1
698	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. 2013 , 72, 64-71	161

697	Etanercept for the treatment of rheumatoid arthritis. 2013 , CD004525	33
696	Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. 2013 ,	2
695	Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. 2013 , 16, 527-31	73
694	Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. 2013 , 32, 1347-55	25
693	A patient with hepatitis C virus infection and inflammatory polyarthritis. 2013 , 65, 1885-91	3
692	Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) of the wrist and finger at 3T: comparison with chemical shift selective fat suppression images. 2013 , 37, 733-8	15
691	'What I want clinicians to know'--experiences of people with arthritis. 2013 , 22, 808-12	10
690	BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats. 2013 , 34, 414-23	15
689	Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort. 2013 , 72, 1335-41	26
688	Treat-to-target: a tailored treatment approach to rheumatoid arthritis. 2013 , 22, 308, 310, 312-8	5
687	Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis. 2013 , 40, 1812-22	27
686	Do the 2010 ACR/EULAR or ACR 1987 classification criteria predict erosive disease in early arthritis?. 2013 , 72, 745-7	9
685	Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2013 , 65, 3036-44	43
684	High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy. 2013 , 20, 842-7	12
683	Are we being open enough to all approaches to therapy of rheumatoid arthritis?. 2013 , 19, 167-71	1
682	Rheumatoid arthritis: preoperative evaluation for total hip and total knee replacement surgery. 2013 , 19, 187-92	9
681	Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimen. 2013 , 52, 1132-40	16
680	Biologics utilization for rheumatoid arthritis in the United States: An observational longitudinal study. 2013 , 13, 74-81	1

679	To what extent is NICE guidance on the management of rheumatoid arthritis in adults being implemented in clinical practice? A regional survey. 2013 , 13, 42-6		6
678	Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. 2013 , 40, 617-23		42
677	Adalimumab: 8 years of experience in rheumatoid arthritis. 2013 , 8, 165-184		1
676	A preliminary investigation of cognitive function in rheumatoid arthritis patients on long-term methotrexate treatment. 2013 , 18, 1353-9		4
675	Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus. 2013 , 16, 408-12		3
674	Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. 2013 , 2013, 313858		23
673	The application of optical coherence tomography in musculoskeletal disease. 2013 , 2013, 563268		11
672	Reply: To PMID 22473917. 2013 , 65, 832-3		3
671	Incorporating data from various trial designs into a mixed treatment comparison model. 2013 , 32, 2935-49		58
670	Level of the indication of biologic agents in the 2012 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis: comment on the article by Singh et al. 2013 , 65, 832		1
669	Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. 2013 , 65, 1504-14		39
668	Pharmacokinetic consideration of synthetic DMARDs in rheumatoid arthritis. 2013 , 9, 969-81		
667	Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice. 2013 , 23, 466-477		13
666	Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort. 2013 , 40, 1823-30		24
665	TNF inhibitor therapy for rheumatoid arthritis. 2013 , 1, 177-184		127
664	The Rheumatology Monitoring Clinic in Singapore [A Novel Advanced Practice Nurse-/Pharmacist-Led Clinic. 2013 , 22, 48-55		8
663	Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies. <i>BMC Musculoskeletal Disorders</i> , 2013 , 14, 332	2.8	14
662	Tuberculous pleurisy diagnosed by medical thoracoscopy in an adalimumab-treated rheumatoid arthritis patient after treatment of latent tuberculosis infection. 2013 , 23, 1013-1017		3

661	Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. 2013 , 17, 1590-5	33
660	Ofatumumab for rheumatoid arthritis. 2013 ,	
659	Tofacitinib for rheumatoid arthritis. 2013 ,	1
658	Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. 2013 , 19, 545-61	105
657	The pitfalls in surgical management of lumbar canal stenosis associated with rheumatoid arthritis. 2013 , 53, 853-60	8
656	Patients with arthritis undergoing surgery: how should we manage tumour necrosis factor blocking agents perioperatively?-A systematic literature review. 2013 , 54, 253-7	4
655	Do We Have to Stop Biologics before Surgery?. 2013 , 19a, 143-146	
654	Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty. 2013 , 19, 49-67	14
653	Small Molecule DMARD Therapy and Its Position in RA Treatment. 2013 ,	1
652	Perioperative Surgical Site Infections and Complications in Elective Orthopedic Surgery in Patients with Rheumatoid Arthritis Treated with Anti-Tumor Necrosis Factor-Alpha Agents Discontinue or Not, Clinical Dilemma. 2013 ,	
651	Eye Infection Complications in Rheumatic Diseases. 2013 ,	2
650	Severe rheumatoid arthritis hand deformity. 2013 , 2013,	
649	Treatment of Rheumatoid Arthritis Patients with Chronic Hepatitis B: Analysis of Korean National Health Insurance Claims Data. 2013 , 20, 24	1
648	Clinical Characteristics of Korean Rheumatoid Arthritis Patients with Indications for TNF-Blocker. 2013 , 20, 356	4
647	Safety and Efficacy Evaluation for the Addition of Either Etanercept or Leflunomide in Korean Rheumatoid Arthritis Patients Inadequately Responding to Methotrexate. 2013 , 20, 166	1
646	Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis. 2014 , 2014, 823763	23
645	Size matters--nanotechnology and therapeutics in rheumatology and immunology. 2014 , 10, 11-21	11
644	CD4(+)CD25(+) regulatory T cells as a therapeutic target in rheumatoid arthritis. 2014 , 39, 100-3	4

643	Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications. 2014 , 5, 516-36	50
642	Predictors of treatment initiation with tumor necrosis factor-inhibitors in patients with rheumatoid arthritis. 2014 , 20, 1110-20	25
641	Prevalence of hepatitis B and C infections in rheumatoid arthritis and ankylosing spondylitis: A multicenter countrywide study. 2014 , 1, 51-54	8
640	Metastatic bone lesion due to methotrexate and etanercept 24 years after breast cancer treatment. 2014 , 2014,	2
639	The future of biological agents in the treatment of rheumatoid arthritis. 2014 , 9, 475-486	
638	Editorial: Arthroplasty outcomes are improving, but why isn't my patient with rheumatoid arthritis doing as well?. 2014 , 66, 250-3	1
637	Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. 2014 , 17 Suppl 3, 9-19	22
636	Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. 2014 , 73, 1774-80	121
635	Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. 2014 , 17, 555-66	21
634	Simvastatin reduces leucocyte- and platelet-endothelial cell interaction in murine antigen-induced arthritis in vivo. 2014 , 43, 356-63	5
633	Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. 2014 , 66, 1619-26	55
632	Inhibitory effects of H-Ras/Raf-1-binding affibody molecules on synovial cell function. 2014 , 4, 82	10
631	Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience. 2014 , 8, 1061-71	29
630	Use of rituximab in pemphigus patients with chronic viral hepatitis: report of three cases. 2014 , 80, 422-6	6
629	Management of Autoimmunity and Inflammation. 2014 , 931-942	
628	High disease activity may not be sufficient to escalate care. 2014 , 66, 197-203	22
627	Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). 2014 , 54, 109-19	23
626	Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis. 2014 , 32, 1015-28	7

625	End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. 2014 , 40, 938-48		31
624	Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). 2014 , 56, 135-58		107
623	Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. 2014 , 30, 1706-15		92
622	Cross-sectional study of self-care safety skills in 677 patients on biologic agents for inflammatory joint disease. 2014 , 81, 502-7		8
621	Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?. 2014 , 15, 1079-90		31
620	Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study. 2014 , 66, 980-9		28
619	Vasculitic Neuropathies and Neuropathies of Connective Tissue Diseases. 2014 , 733-785		3
618	Current Practice Patterns and Educational Needs of Rheumatologists Who Manage Patients with Rheumatoid Arthritis. 2014 , 1, 31-44		8
617	Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. <i>BMC Musculoskeletal Disorders</i> , 2014 , 15, 449	2.8	20
616	Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs—a systematic review and network meta-analysis. 2014 , 12, 102		39
615	Practice guidelines for pharmacists: The pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. 2014 , 147, 97-109		9
614	Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region. 2014 , 20, 25-33		31
613	Variations and practice in the care of patients with rheumatoid arthritis: quality and cost of care. 2014 , 20, 79-86		8
612	Hepatobiliary manifestations of inflammatory bowel disease. 2014 , 20, 1655-67		17
611	Fertility and infertility in rheumatoid arthritis. 2014 , 26, 308-14		36
610	Clinical features, diagnosis, and natural history of drug-induced liver injury. 2014 , 34, 134-44		48
609	Individualization of leflunomide dosing in rheumatoid arthritis patients. 2014 , 11, 449-461		5
608	Thymidine phosphorylase regulates the expression of CXCL10 in rheumatoid arthritis fibroblast-like synoviocytes. 2014 , 66, 560-8		22

607	Methotrexate induced pancytopenia. 2014 , 2014, 679580	9
606	[Self-monitoring in inflammatory rheumatic diseases]. 2014 , 73, 706-13	0
605	Arthritides. 2014 , 476-624	2
604	Development and retrospective validation of the juvenile spondyloarthritis disease activity index. 2014 , 66, 1775-82	49
603	Pulmonary Embolism following Cessation of Infliximab for Treatment of Miliary Tuberculosis. 2014 , 2014, 479025	
602	Serodiagnosis of Mycobacterium avium complex pulmonary disease in rheumatoid arthritis. 2014 , 87, 129-35	8
601	Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. 2014 , 3, e001267	44
600	How do anti-TNF therapies affect gait function in patients with rheumatoid arthritis?. 2014 , 17, 57-62	4
599	Lymphopenia induced by etanercept. 2014 , 112, 262-3	2
598	From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. 2014 , 70, 178-86	50
597	Rheumatoid arthritis pharmacotherapy and predictors of disease-modifying anti-rheumatic drug initiation in the early years of biologic use in Quebec, Canada. 2013 , 34, 75	7
596	Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis--the Health Outcomes Patient Environment (HOPE) study. 2014 , 34, 25-33	26
595	Prosthetic joint infection. 2014 , 27, 302-45	857
594	[Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases]. 2014 , 73, 77-84	14
593	Early start and stop of biologics: has the time come?. 2014 , 12, 25	20
592	Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. 2014 , 66, 803-12	121
591	Hepatologische Aspekte der immunsuppressiven Therapie rheumatologischer Erkrankungen. 2014 , 39, 182-185	2
590	Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. 2014 , 81, 478-84	21

589	Maladies systémiques et biomédicaments : comprendre, apprécier et prévenir le risque de réactivation d'hépatite B. 2014 , 81, 374-380		
588	Choosing Wisely: the American College of Rheumatology's Top 5 for pediatric rheumatology. 2014 , 66, 649-57		10
587	Pulmonary Manifestations of Rheumatic Disease. 2014 ,		2
586	Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. 2014 , 121, 785-96.e3		308
585	Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1841-7	4-3	51
584	Antiinflammatory and analgesic effect of herbal cocktail Hongbaekjeong via inhibition of proinflammatory cytokines and prostaglandin E2 release. 2014 , 59, 3127-3133		1
583	The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. 2014 , 127, 1208-32		78
582	Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. 2014 , 73, 536-43		74
581	Trends in medication usage in juvenile idiopathic arthritis: prescribing trends or trends in prescribers?. 2014 , 41, 1903-5		0
580	Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. 2014 , 81, 287-97		100
579	Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. 2014 , 81, 303-312		7
578	Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial. 2014 , 14, 48-53		24
577	Biologika und Zeugung. 2014 , 13, 18-21		
576	A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated inflammatory arthritis: study protocol for a randomized controlled trial. 2014 , 15, 268		3
575	Vaccines and biologics. 2014 , 73, 1446-54		22
574	The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid. 2014 , 32, 593-600		19
573	Diagnosing and treating psoriatic arthritis: an update. 2014 , 170, 772-86		23
572	Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. 2014 , 31, 410-25		20

571	Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. 2014 , 12, 31	16
570	The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. 2014 , 10, 1049-57	34
569	Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses. 2014 , 171, 1307-17	15
568	Maternal hemoglobin levels during pregnancy and asthma in childhood: the Generation R Study. 2014 , 112, 263-5	6
567	Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record. 2014 , 66, 1159-66	43
566	The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database. 2014 , 34, 1729-36	9
565	When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations. 2014 , 1318, 32-40	20
564	ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. 2014 , 109, 950-66; quiz 967	469
563	Improving treatment with methotrexate in rheumatoid arthritis-development of a multimedia patient education program and the MiRAK, a new instrument to evaluate methotrexate-related knowledge. 2014 , 43, 437-46	16
562	Five-year administration of tocilizumab to a patient with rheumatoid arthritis complicated by severe chronic heart failure. 2014 , 37, 488-92	4
561	Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro 1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. 2014 , 4, 349-60	50
560	A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. 2015 , 67, 3104-12	18
559	Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece. 2015 , 7, 85-93	1
558	Oral clindamycin causing acute cholestatic hepatitis without ductopenia: a brief review of idiosyncratic drug-induced liver injury and a case report. 2015 , 5, 28746	5
557	Guided Imagery for Arthritis and Other Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials. 2015 , 16, 792-803	27
556	Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. 2015 , 17, 289	29
555	Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study. 2015 , 17, 295	22
554	Methotrexate utilization in Rheumatoid arthritis. A register-based cohort-study of treatment re-starts after gabs of at least 90 days. 2015 , 4, 227	1

553	Subcutaneous or intramuscular methotrexate for rheumatoid arthritis. 2015 ,	
552	Impact of Bariatric Surgery on Patients With Rheumatoid Arthritis. 2015 , 67, 1619-26	37
551	Chronic liver injury induced by drugs: a systematic review. 2015 , 35, 2343-53	65
550	Drug-induced liver injury in children. 2015 , 27, 625-33	17
549	Implications of Rheumatic Disease and Biological Response-Modifying Agents in Plastic Surgery. 2015 , 136, 1327-1336	5
548	Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population. 2015 , 67, 1646-55	34
547	Biological therapy for Rheumatoid Arthritis ? an update. 2015 , 10, 99-102	
546	Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. 2015 , 7, 344-61	56
545	Incidence of Tuberculosis in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents following Latent Tuberculosis Infection Screening Strategies. 2015 , 22, 223	3
544	The Peri-operative Management of the Rheumatoid Patient Undergoing Total Knee Arthroplasty: A Review of Literature. 2015 , 11, 34-38	3
543	Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. 2015 , 21, 409-23	63
542	Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population. 2015 , 21, 318-29	25
541	An Insight into Methods and Practices in Hip Arthroplasty in Patients with Rheumatoid Arthritis. 2015 , 2015, 140143	7
540	Enhanced evidence-based chinese medicine clinical practice guidelines in Hong Kong: a study protocol for three common diseases. 2015 , 2015, 482706	6
539	To Biopsy or not to Biopsy: A Review of Guidelines on the use of Methotrexate. 2015 , 1, 31-37	
538	Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis. 2015 , 30, 227-30	7
537	Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. 2015 , 17, 136	11
536	Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006-2012. 2015 , 9, e0003603	137

535	Tumor necrosis factor- α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study. 2015 , 34, 1039-46	10
534	Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials. 2015 , 45, 156-62	51
533	Subjective numeracy and preference to stay with the status quo. 2015 , 35, 6-11	26
532	Can the publication of guidelines change the management of early rheumatoid arthritis? An interrupted time series analysis from the United Kingdom. 2015 , 54, 2244-8	9
531	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. 2015 , 17, 307	36
530	Rheumatoid Arthritis: Trends in Antirheumatic Drug Use, C-reactive Protein Levels, and Surgical Burden. 2015 , 42, 2247-54	11
529	Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. 2015 , 5, e006560	8
528	Treatment Considerations of Lung Involvement in Rheumatologic Disease. 2015 , 90, 265-74	12
527	Arthroplasty in patients with established rheumatoid arthritis (RA): Mitigating risks and optimizing outcomes. 2015 , 29, 628-42	19
526	Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases. 2015 , 29, 319-42	10
525	Safety issues and concerns of new immunomodulators in rheumatology. 2015 , 14, 389-99	30
524	Biosimilars: clinical interpretation and implications for drug development. 2015 , 17, 8	3
523	Rheumatoid arthritis: Perioperative management of biologics and DMARDs. 2015 , 44, 627-32	51
522	Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions. 2015 , 44, 506-513	14
521	Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. 2015 , 9, 202-8	28
520	Étude transversale des compétences de sécurité de 677 patients traités par biomédicament pour un rhumatisme inflammatoire. 2015 , 82, 29-34	
519	Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. <i>Inflammopharmacology</i> , 2015 , 23, 71-75.1	21
518	The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. 2015 , 74, 430-6	49

517	Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. 2015 , 25, 50-5	3
516	Postoperative complications in patients with rheumatoid arthritis using a biological agent - A systematic review and meta-analysis. 2015 , 25, 672-8	23
515	Improving clinical practice guideline development in integration of traditional Chinese medicine and Western medicine. 2015 , 21, 163-5	8
514	Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection. 2015 , 67, 467-74	13
513	Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. 2015 , 18, 376-89	14
512	A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. 2015 , 25, 344-9	14
511	Diagnosis, Management, and Prevention of Hepatitis B Reactivation. 2015 , 14, 184-194	
510	Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. 2015 , 25, 514-21	93
509	Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. 2015 , 350, h1269	65
508	Advances in use of immunomodulatory agents--a rheumatology perspective. 2015 , 12, 363-8	14
507	Compromiso hepático de las enfermedades autoinmunes sistémicas. 2015 , 22, 47-58	1
506	Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. 2015 , 35, 1525-34	10
505	[Differential diagnosis of elevated liver transaminases in rheumatic diseases]. 2015 , 74, 137-45	1
504	Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers. 2015 , 191, 1403-12	100
503	Drug-loaded gold/iron/gold plasmonic nanoparticles for magnetic targeted chemo-photothermal treatment of rheumatoid arthritis. 2015 , 61, 95-102	97
502	Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management. 2015 , 32, 361-9	7
501	Review of tofacitinib in rheumatoid arthritis. 2015 , 5, 23-38	5
500	Thyroid-specific changes following treatment with biological therapies in patients with rheumatic diseases. 2015 , 50, 146-53	5

499	Recognizing and managing comorbidities in psoriatic arthritis. 2015 , 27, 118-26	116
498	Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists. 2015 , 16, 179-95	5
497	Oral low-dose glucocorticoids should be included in any recommendation for the use of non-biologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. 2015 , 22, 104-11	10
496	Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study. 2015 , 35, 1825-36	7
495	Remission in SLE: closing in on the target. 2015 , 74, 2103-6	15
494	Characteristics of traditional Chinese medicine use in patients with rheumatoid arthritis in Taiwan: A nationwide population-based study. 2015 , 176, 9-16	48
493	APLAR rheumatoid arthritis treatment recommendations. 2015 , 18, 685-713	93
492	Post-Chikungunya rheumatoid arthritis, Saint Martin. 2015 , 21, 530-2	27
491	The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor- α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies. 2015 , 42, 2229-37	69
490	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. 2015 , 54, 1780-91	55
489	Methotrexate modulates the expression of MMP-1 and type 1 collagen in dermal fibroblast. 2015 , 409, 213-24	16
488	Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis. 2015 , 28, 802-7	31
487	Comparison of Photo Optical Imaging with Musculoskeletal Ultrasound and Clinical Examination in the Assessment of Inflammatory Activity in Proximal Interphalangeal Joints in Rheumatoid Arthritis and Osteoarthritis. 2015 , 42, 1595-602	5
486	How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease. 2015 , 351, h3658	8
485	Comorbidities in Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 677-98	2.4 83
484	Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. 2016 , 55, 573-82	30
483	Pharmacology Update on Chronic Obstructive Pulmonary Disease, Rheumatoid Arthritis, and Major Depression. 2015 , 50, 761-70	1
482	Assessment of previous tuberculosis status using questionnaires, chest X-rays and computed tomography scans. 2015 , 19, 1435-40	6

481	Improving the quality of care of patients with rheumatic disease using patient-centric electronic redesign software. 2015 , 67, 546-53		24
480	Inhibition of PCSK6 may play a protective role in the development of rheumatoid arthritis. 2015 , 42, 161-9		13
479	Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. 2015 , 34, 215-20		17
478	Methotrexate-associated lymphoproliferative disorders of the tongue developing in patients with rheumatoid arthritis: a report of 2 cases and a review. 2015 , 119, e1-5		12
477	Recommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration routes. 2015 , 11, 3-8		19
476	Recommendations for the Use of Methotrexate in Rheumatoid Arthritis: Up and Down Scaling of the Dose and Administration Routes. 2015 , 11, 3-8		
475	Mycobacterium tuberculosis promotes arthritis development through Toll-like receptor 2. 2015 , 33, 135-41		15
474	Rheumatoid arthritis in patients with HIV: management challenges. 2016 , 8, 51-59		9
473	Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis. 2016 , 22, 122-30		19
472	An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. 2016 , 22, 1088-102		23
471	Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making. 2016 , 10, 1079-90		22
470	Idiopathic Inflammatory Myopathies: Clinical Approach and Management. 2016 , 7, 64		65
469	Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 231	2.8	41
468	Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 348	2.8	
467	Implementation of disease activity measurement for rheumatoid arthritis patients in an academic rheumatology clinic. 2016 , 16, 384		7
466	Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. 2016 , 8, 707-715		22
465	Methylene Blue is a Monoamine Oxidase Inhibitor; Severe Harm and Death Associated with Low-Dose Methotrexate; Potentially Dangerous Mix-up between Cancer Drugs. 2016 , 51, 110-114		3
464	Self-Reported Barriers to Healthcare Access for Rheumatoid Arthritis Patients in Rural and Northern Saskatchewan: A Mixed Methods Study. 2016 , 14, 243-251		15

463	Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection. 2016 , 68, 738-43	35
462	Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis. 2016 , 22, 57-62	11
461	The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Should Include New Standards for Hepatitis B Screening: Comment on the Article by Singh et al. 2016 , 68, 1314-5	2
460	3D Biomaterial Microarrays for Regenerative Medicine: Current State-of-the-Art, Emerging Directions and Future Trends. 2016 , 28, 771-81	71
459	Efficacy and safety of weekly leflunomide for the treatment of early rheumatoid arthritis: a randomized, multi-center study. 2016 , 19, 651-7	2
458	Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story. 2016 , 19, 844-51	28
457	Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage. 2016 , 2, e000186	9
456	Pneumocystis pneumonia complicating immunosuppressive therapy in Crohns disease: A preventable problem?. 2016 , 7, 222-226	5
455	Low levels of inflammation and the absence of subclinical atherosclerosis in rheumatoid arthritis. 2016 , 13, 3521-4	4
454	(99) Tc-methylene diphosphonate improves rheumatoid arthritis disease activity by increasing the frequency of peripheral Γ cells and CD4(+) CD25(+) Foxp3(+) Tregs. 2016 , 19, 586-93	12
453	Rheumatoid arthritis triple therapy compared with etanercept: difference in infectious and gastrointestinal adverse events. 2017 , 56, 378-383	3
452	Early rheumatoid arthritis: Clinical and functional outcomes of a cohort treated in a high complexity hospital, Cali-Colombia. 2016 , 23, 148-154	
451	One-year maintenance with routine assessment of patient index data 3-based remission may inhibit radiographic progression in patients with rheumatoid arthritis treated with routine clinical therapy: A retrospective comparison of radiographic outcome and its prognostic factors between maintained remissions with patient-reported outcome index and physician-oriented disease activity indices. 2016 , 26, 817-827	2
450	Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions. 2016 , 100, 719-31	11
449	Iridoid glycosides from the flowers of Gentiana macrophylla Pall. ameliorate collagen-induced arthritis in rats. 2016 , 189, 1-9	28
448	Treatment with Adenosine Receptor Agonist Ameliorates Pain Induced by Acute and Chronic Inflammation. 2016 , 358, 315-23	16
447	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. 2016 , 55, 1031-41	46
446	Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. 2016 , 38, 1359-1375.e1	10

445	Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs. 2016 , 35, 1475-81	19
444	Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal. 2016 , 35, 2163-73	4
443	Gold coated magnetic nanoparticles: from preparation to surface modification for analytical and biomedical applications. 2016 , 52, 7528-40	141
442	Influence of triple disease modifying anti-rheumatic drug therapy on carotid artery inflammation in drug-naïve patients with recent onset of rheumatoid arthritis. 2016 , 55, 1777-85	7
441	Artritis reumatoide temprana: resultados clínicos y funcionales de una cohorte en un centro de alta complejidad, Cali-Colombia. 2016 , 23, 148-154	0
440	Safety and efficacy of the leukocytapheresis procedure in eighty-five patients with rheumatoid arthritis. 2016 , 55, 225-232	4
439	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. 2016 , 19, 1216-1225	18
438	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 , 68, 1-25	717
437	Neutropenia in the Elderly: A Rheumatology Perspective. 2016 , 33, 585-601	4
436	From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. 2016 , 75, 798-805.e7	16
435	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 , 68, 1-26	1274
434	Association of 63/91 length polymorphism in the DHFR gene major promoter with toxicity of methotrexate in patients with rheumatoid arthritis. 2016 , 17, 1687-1691	6
433	Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children. 2016 , 138,	37
432	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). 2016 , 11, CD012437	18
431	Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria. 2016 , 55, 1954-1958	6
430	Use of Low-Literacy Decision Aid to Enhance Knowledge and Reduce Decisional Conflict Among a Diverse Population of Adults With Rheumatoid Arthritis: Results of a Pilot Study. 2016 , 68, 889-98	34
429	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. 2016 , CD012183	36
428	Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. 2016 , 68, 1751-1757	21

427	Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review. 2016 , 33, 1094-104	16
426	Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. 2016 , 18, 94	6
425	Periprosthetic Joint Infections. 2016 ,	2
424	The Endo-Model(®) rotating hinge for rheumatoid knees : Functional results in primary and revision surgery. 2016 , 45, 446-51	9
423	The 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Should Include New Standards for Hepatitis B Screening: Comment on the Article by Singh et al. 2016 , 68, 723-4	12
422	The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis. 2016 , 26, 51-6	6
421	Pharmacology and Drug Therapy: Nonbiologic Therapies. 2016 , 140-160.e16	
420	Pharmacology. 2016 , 161-175.e6	5
419	A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. 2016 , 36, 685-95	154
418	Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. 2016 , 19, 568-75	11
417	Strategies for the optimal use of biologic agents in rheumatoid arthritis. 2016 , 93-107	
416	The association between serious infection and disease outcome in patients with rheumatoid arthritis. 2016 , 35, 213-8	7
415	Preoperative and Postoperative Medical Management for Rheumatoid Hand Surgery. 2016 , 21-30	
414	Medication Management for Patients on Rheumatologic Agents or Chronic Steroids. 2016 , 5, 268-280	1
413	Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis. 2016 , 414, 85-94	2
412	Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients. 2016 , 17, 25-9	29
411	Gist and verbatim communication concerning medication risks/benefits. 2016 , 99, 988-94	4
410	The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis. 2016 , 17, 703-14	7

409	The process of collecting and evaluating evidences for the development of Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology 2014: Utilization of GRADE approach. 2016 , 26, 175-9	9
408	Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care. 2016 , 69, 235-44	2
407	Immunological evaluation of rheumatoid arthritis patients treated with itolizumab. 2016 , 8, 187-95	13
406	Risk factors for surgical site infection and delayed wound healing after orthopedic surgery in rheumatoid arthritis patients. 2016 , 26, 68-74	22
405	Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014. 2016 , 10, 139-46	7
404	Comment on "Tumor necrosis factor- α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study". 2016 , 35, 839-40	1
403	Protective Effect of Infliximab, a Tumor Necrosis Factor- α Inhibitor, on Bleomycin-Induced Lung Fibrosis in Rats. 2016 , 39, 65-78	25
402	B cells influence sex specificity of arthritis via myeloid suppressors and chemokines in humanized mice. 2017 , 178, 10-19	8
401	Are RA patients from a non-endemic HCV population screened for HCV? A cross-sectional analysis of three different settings. 2017 , 13, 156-159	1
400	Consensus development on eligibility of government subsidisation of biologic disease modifying anti-rheumatic agents for treatment of ankylosing spondylitis: The Singapore experience. 2017 , 20, 1517-1526	5
399	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Oencia in Rheumatoid Arthritis Registry. 2017 , 56, 629-637	7
398	Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. 2017 , 20, 464-473	24
397	Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap. 2017 , 76, 1057-1063	80
396	Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty. 2017 , 69, 1845-1854	45
395	Exacerbation d'infection par le virus de l'hépatite E au cours d'un traitement par anti-TNF- α 2017 , 84, 244-247	
394	Methotrexate-induced pancytopenia: a case series of 46 patients. 2017 , 20, 846-851	21
393	Infectious tenosynovitis with bloodstream infection caused by <i>Erysipelothrix rhusiopathiae</i> , a case report on an occupational pathogen. 2017 , 17, 12	3
392	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. 2017 , 3, CD012591	29

391	Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials. 2017 , 177, 978-986	25
390	Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review. 2017 , 44, 773-779	3
389	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. 2017 , 5, CD012657	33
388	Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. 2017 , 76, 1559-1565	57
387	Nonbiologic Drugs in Pediatric Rheumatology. 2017 , 55-75	
386	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. 2017 , 34, 2422-2435	23
385	Anti-Rheumatic Therapy and Comorbidity. 2017 , 345-380	
384	2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. 2017 , 20, 1166-1184	7
383	Are RA patients from a non-endemic HCV population screened for HCV? A cross-sectional analysis of three different settings. 2017 , 13, 156-159	
382	Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis. 2017 , 19, 54	9
381	Update in perioperative medicine: practice changing evidence published in 2016. 2017 , 45, 158-164	5
380	Modelling the cost-effectiveness of statin therapy in rheumatoid arthritis: a Markov-cycle evaluation from national data bank for rheumatic diseases. 2017 , 8, 139-145	
379	Severe Harm and Death Associated With Errors and Drug Interactions Involving Low-Dose Methotrexate. 2017 , 35, 519-522	1
378	Periprocedural medication management. 2017 , 9, 12-15	
377	Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy. 2017 , 34, 1936-1952	35
376	Whole grape alleviates inflammatory arthritis through inhibition of tumor necrosis factor. 2017 , 35, 458-465	6
375	Factors associated with hand joint destruction in Chinese patients with rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 211	2.8 5
374	Hepatitis B Reactivation in Rheumatic Diseases: Screening and Prevention. <i>Rheumatic Disease Clinics of North America</i> , 2017 , 43, 133-149	2.4 29

373	Exacerbation of hepatitis E virus infection during anti-TNF α treatment. 2017 , 84, 217-219	6
372	Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. 2017 , 32, 769-777	20
371	Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. 2017 , 69, 313-322	24
370	Methotrexate intolerance in the treatment of rheumatoid arthritis (RA): effect of adding caffeine to the management regimen. 2017 , 36, 279-285	12
369	Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNF α . 2017 , 84, 441-445	14
368	Methotrexate improves perivascular adipose tissue/endothelial dysfunction via activation of AMPK/eNOS pathway. 2017 , 15, 2353-2359	16
367	Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. 2017 , 356, j895	35
366	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. 2017 , 958-982.e7	2
365	Managing Rheumatoid Arthritis with Dietary Interventions. 2017 , 4, 52	54
364	Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. 2017 , 2017, 9614241	13
363	Microbiome. 2017 , 569-583	1
362	Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 310	2.8 17
361	Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. 2017 , 19, 159	23
360	A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial. 2017 , 19, 215	7
359	Characteristics and risk factors of rheumatoid arthritis in the United States: an NHANES analysis. 2017 , 5, e4035	15
358	The Gut Microbiota and Inflammation in Rheumatoid Arthritis. 2017 ,	
357	Bacterial Arthritis. 2017 , 1876-1890	1
356	La prothèse inversée de l'épaule dans la polyarthrite rhumatoïde. 2018 , 85, 138-144	

- 355 Lung Disease in Rheumatoid Arthritis. **2018**,
- 354 Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink. **2018**, 57, 977-981 29
- 353 Effects of Artesunate on chondrocyte proliferation, apoptosis and autophagy through the PI3K/AKT/mTOR signaling pathway in rat models with rheumatoid arthritis. **2018**, 102, 1209-1220 105
- 352 Clinical connection between rheumatoid arthritis and liver damage. **2018**, 38, 715-724 23
- 351 Next Generation Biopharmaceuticals: Product Development. **2018**, 165, 253-276 1
- 350 Predictors for orthopaedic surgery in patients with rheumatoid arthritis: results from a retrospective cohort study of 1010 patients diagnosed from 1972 to 2009 and followed up until 2015. **2018**, 47, 282-290 4
- 349 A novel combination of astilbin and low-dose methotrexate respectively targeting AAR and its ligand adenosine for the treatment of collagen-induced arthritis. **2018**, 153, 269-281 16
- 348 Have the Annual Trends of Total Knee Arthroplasty in Rheumatoid Arthritis Patients Changed?. **2018**, 31, 841-845 3
- 347 Skin Exposure Issues. **2018**, 63-73
- 346 Anti-arthritic properties of crude extract from *Chenopodium ambrosioides* L. leaves. **2018**, 70, 1078-1091 6
- 345 Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. **2018**, 77, 898-904 85
- 344 Consistent estimation of polychotomous treatment effects with selection-bias and unobserved heterogeneity using panel data correlated random coefficients model. **2018**, 18, 75-95
- 343 Flares in Patients with Rheumatoid Arthritis after Total Hip and Total Knee Arthroplasty: Rates, Characteristics, and Risk Factors. **2018**, 45, 604-611 28
- 342 Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months. **2018**, 21, 1001-1009 3
- 341 Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial. **2018**, 85, 59-64 8
- 340 Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. **2018**, 70, 30-38 7
- 339 Rheumatoid arthritis and cancer risk[BULLET OPERATOR]results from the Greek European prospective investigation into cancer and nutrition cohort. **2018**, 27, 502-506 3
- 338 Dendrimers: Breaking the paradigm of current musculoskeletal autoimmune therapies. **2018**, 12, e1796-e1812 5

- 337 Infections Related to Biologic Modifier Therapy. **2018**, 651-656.e3
- 336 Adoptive Induced Antigen-Specific Treg Cells Reverse Inflammation in Collagen-Induced Arthritis Mouse Model. **2018**, 41, 485-495 17
- 335 Drug-Induced Gastrointestinal and Hepatic Disease Associated with Biologics and Nonbiologic Disease-Modifying Antirheumatic Drugs. *Rheumatic Disease Clinics of North America*, **2018**, 44, 29-43 2.4 10
- 334 Gastrointestinal and Hepatic Disease in Spondyloarthritis. *Rheumatic Disease Clinics of North America*, **2018**, 44, 153-164 2.4 1
- 333 Dried plum alleviates symptoms of inflammatory arthritis in TNF transgenic mice. **2018**, 52, 54-61 12
- 332 Évaluation du risque infectieux suite à une chirurgie orthopédique chez des patients ayant une polyarthrite rhumatoïde sous anti TNF-α. **2018**, 85, 7-11
- 331 The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients. **2018**, 9, 6615-6622 18
- 330 Evaluation of the effect of vitamin C on caspase 9 and oxidative stress in rheumatoid arthritis patients. **2018**, 12, 94-101 2
- 329 Galangin protects human rheumatoid arthritis fibroblast-like synoviocytes via suppression of the NF-κB/NLRP3 pathway. **2018**, 18, 3619-3624 14
- 328 Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. **2018**, 38, 646-652 20
- 327 Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations. **2018**, 33, 251-271 1
- 326 Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome. **2018**, 4, e000739 1
- 325 NEW COMBINATION SUPPOSITORIES OF LORNOXICAM AND ALOIN FOR RHEUMATOID ARTHRITIS. **2018**, 11, 308 0
- 324 Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data. **2018**, 38, 2111-2120 18
- 323 Transient Elastography for Monitoring for Hepatotoxicity in Rheumatoid Arthritis Patients on Long-term Methotrexate. **2021**, 27, e131-e134 1
- 322 Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. **2018**, 158, 502-516 155
- 321 Nephrotoxicity of Select Rheumatologic Drugs. *Rheumatic Disease Clinics of North America*, **2018**, 44, 605-617 2.4 3
- 320 Renal Manifestations of Rheumatoid Arthritis. *Rheumatic Disease Clinics of North America*, **2018**, 44, 571-584 16

319	Ginseng-Related Drug-Induced Liver Injury. 2018 , 12, 439-446	8
318	Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. 2018 , 17, 1138-1149	47
317	Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study. 2018 , 33, e168	
316	Hepatitis E during Tocilizumab Therapy in a Patient with Rheumatoid Arthritis: Case Report and Literature Review. 2018 , 2018, 6873276	5
315	Preparing patients for biologic medications for dermatologic and rheumatic diseases. 2018 , 31, 23-28	1
314	Methionine attenuates the intensity of rheumatoid arthritis by downregulating NF- κ B and iNOS expression in neonatal rats. 2018 , 8, 303	3
313	Drugs Used in Rheumatic Disease. 2018 , 15, 39-76	2
312	Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. 2018 , 45, 1353-1360	6
311	Atherosclerosis and inflammation: overview and updates. 2018 , 132, 1243-1252	317
310	Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease. 2018 , 314, L998-L1009	43
309	Modulatory effect of eugenol on arginase, nucleotidase, and adenosine deaminase activities of platelets in a carrageenan-induced arthritis rat model: A possible anti-arthritic mechanism of eugenol. 2018 , 106, 1616-1623	5
308	Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate. 2018 , 10, 97-101	1
307	Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis. 2018 , 20, 130	7
306	An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. 2018 , 24, 1010-1017	12
305	A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases. 2018 , 12, 954-962	17
304	Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study. 2018 , 20, 81	3
303	Lemon-Peel extract ameliorates rheumatoid arthritis by reducing xanthine oxidase and inflammatory cytokine levels. 2018 , 93, 54-62	5
302	Acute and Chronic Therapies in Pediatric Inflammatory Central Nervous System Diseases. 2018 , 16, 202-216	1

301	Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome. 2018 , 36, 733-739	29
300	Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population. 2018 , 5, 355-369	23
299	The Utility of Screening for Coccidioidomycosis in Recipients of Inhibitors of Tumor Necrosis Factor 2019 , 68, 1024-1030	6
298	The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend. 2019 , 58, 580-587	7
297	The Effect of Pre-Appointment Consultation Triage on Patient Selection and Revenue Generation in a University Rheumatology Practice. 2019 , 71, 689-693	1
296	Contemporary optimized practice in the management of pulmonary sarcoidosis. 2019 , 13, 1753466619868935	7
295	Thoracic Manifestations of Rheumatoid Arthritis. 2019 , 40, 545-560	33
294	Automatic Radiographic Quantification of Joint Space Narrowing Progression in Rheumatoid Arthritis Using POC. 2019 ,	3
293	The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry. 2019 , 38, 3081-3092	4
292	Assessing the development and treatment of rheumatoid arthritis using multiparametric photoacoustic and ultrasound imaging. 2019 , 12, e201900127	8
291	Early Lyme Borreliosis in Patients Treated with Tumour Necrosis Factor-Alpha Inhibitors. 2019 , 8,	6
290	Gestion pharmaceutique des biothérapies en 2019. 2019 , 5, 274-284	1
289	Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. 2019 , 25, 1218-1228	1
288	Methotrexate an Old Drug with New Tricks. 2019 , 20,	99
287	Rheumatologists' awareness of hepatitis B reactivation before immunosuppressive therapy. 2019 , 39, 2077-2085	3
286	Targeted hexagonal Pd nanosheet combination therapy for rheumatoid arthritis via the photothermal controlled release of MTX. 2019 , 7, 112-122	25
285	Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRE validation study (INTERStitial pneumonia in rheumatoid Arthritis with an electronic device). 2019 , 19, 111	24
284	A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients. 2019 , 21, 153	31

283	Extra-articular Manifestations and Comorbidity in Rheumatoid Arthritis: Potential Impact of Pre-Rheumatoid Arthritis Prevention. 2019 , 41, 1246-1255	11
282	"Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency?". 2019 , 18, 765-769	9
281	Systematic Appraisal of the American College of Rheumatology Clinical Practice Guidelines. 2019 , 1, 188-193	4
280	Anaphylaxis Induced by Biologics. 2019 , 6, 125-141	4
279	Development of methotrexate-loaded cubosomes with improved skin permeation for the topical treatment of rheumatoid arthritis. 2019 , 9, 1781-1796	13
278	Exploiting CD22 To Selectively Tolerize Autoantibody Producing B-Cells in Rheumatoid Arthritis. 2019 , 14, 644-654	16
277	Noninvasive Tests to Monitor Methotrexate-Induced Liver Injury. 2019 , 13, 67-71	12
276	Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction. 2019 , 6, 1801671	32
275	Current pharmacotherapies for atherosclerotic cardiovascular diseases. 2019 , 42, 206-223	6
274	A systematic review of the factors associated with the initiation of biologicals in patients with rheumatological conditions. 2019 , 26, 163-169	1
273	Baricitinib for rheumatoid arthritis. 2019 ,	2
272	Rheumatology Laboratory Tests. 2019 , 4, 487-500	
271	Nanoparticle-Mediated Oxidative Stress Monitoring and Role of Nanoparticle for Treatment of Inflammatory Diseases. 2019 , 97-112	2
270	The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients. 2019 , 58, 131-134	5
269	Identifying Preanalytic and Postanalytic Laboratory Quality Gaps Using a Data Warehouse and Structured Multidisciplinary Process. 2019 , 143, 518-524	3
268	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. 2019 , 4, 31-58	6
267	Safety evaluation of adalimumab in immune-mediated inflammatory disorders: a rheumatological point of view. 2019 , 18, 11-19	0
266	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. 2019 , 380, 752-762	538

265	Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. 2019 , 30, 668-673	7
264	Group therapy in a cohort study of Egyptian patients with rheumatoid arthritis. 2019 , 22, 614-618	
263	Surgical management of the rheumatoid hand and wrist. 2019 , 33, 23-29	1
262	Tart Cherry Prevents Bone Loss through Inhibition of RANKL in TNF-Overexpressing Mice. 2018 , 11,	7
261	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. 2019 , 71, 5-32	178
260	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. 2019 , 71, 2-29	137
259	Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. 2019 , 29, 31-40	56
258	A Case-Based Guide to Neuromuscular Pathology. 2020 ,	0
257	Metatarsalgia. 2020 , 493-496	
256	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. 2020 , 50, 1085-1090	38
255	Shoulder arthroplasty for juvenile idiopathic arthritis. 2020 , 28, 2309499019890615	1
254	Risk prediction of degenerative scoliosis combined with lumbar spinal stenosis in patients with rheumatoid arthritis: a case-control study. 2020 , 40, 925-932	
253	Clinical Effectiveness and Safety of Treatment With Anti-Tumor Necrosis Factor Drugs in a Cohort of Colombian Patients With Rheumatoid Arthritis. 2020 , 26, S123-S130	2
252	Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment. 2019 , 39, 101906	22
251	Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. 2020 , 16, 207-228	18
250	Interstitial Lung Disease in Elderly Rheumatoid Arthritis Patients. 2020 , 37, 11-18	6
249	Incidence and Complication Rates for Total Hip Arthroplasty in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Across Four Decades. 2020 , 7, 685-702	7
248	Infection risk stratification in total knee joint arthroplasty using a new scoring system. 2020 , 12, 8394	1

247	Effects of mannuronic acid (M2000) on gene expression profile of signal transducer and activator of transcription proteins (STATs) in rheumatoid arthritis patients. 2020 , 72, 93-102	1
246	Long-term hydroxychloroquine therapy improves the quality of sleep in patients with primary Sjögren's syndrome: a real-world study. 2020 , 9, 2203-2210	2
245	Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort. 2020 , 50, 915-922	2
244	Developing Appropriateness Criteria for Pediatric Vascular Access. 2020 , 145, S233-S242	4
243	Near-infrared fluorescence imaging-guided focused ultrasound-mediated therapy against Rheumatoid Arthritis by MTX-ICG-loaded iRGD-modified echogenic liposomes. 2020 , 10, 10092-10105	14
242	Rheumatoid Arthritis Saudi Database (RASD): Disease Characteristics and Remission Rates in a Tertiary Care Center. 2020 , 12, 139-145	6
241	Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records. 2021 , 48, 1472-1479	4
240	Functional outcome of total knee replacement for inflammatory arthritis of knee. 2020 , 221049172097184	0
239	Assessing the incidence of skin and soft tissue infection in patients on biologics. 2021 , 85, 604-610	4
238	Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-An interim report. 2020 , 29, 803-810	4
237	Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study. 2020 , 11, 2040622320922019	5
236	Development of an application for management of drug holidays in perioperative periods. 2020 , 99, e20142	1
235	Sulfasalazine in dermatology: A lesser explored drug with broad therapeutic potential. 2020 , 6, 191-198	2
234	Antitumour necrosis factor- α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. 2020 , 7, e000349	7
233	Effect of phenolic compounds from <i>Oenothera rosea</i> on the kaolin-carrageenan induced arthritis model in mice. 2020 , 253, 112711	6
232	Views on glucocorticoid therapy in rheumatology: the age of convergence. 2020 , 16, 239-246	31
231	Disease activity-based management of rheumatoid arthritis in Dutch daily clinical practice has improved over the past decade. 2020 , 39, 1131-1139	1
230	Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. 2020 , 9,	33

229	Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease. 2020 , 2020, 6390749	7
228	Methotrexate and rheumatoid arthritis associated interstitial lung disease. 2021 , 57,	34
227	Autoantibody Seropositivity and Risk for Interstitial Lung Disease in a Prospective Male-Predominant Rheumatoid Arthritis Cohort of U.S. Veterans. 2021 , 18, 598-605	5
226	Traditional and modern management strategies for rheumatoid arthritis. 2021 , 512, 142-155	6
225	Hydroxychloroquine prescribing habits and impact of the COVID-19 pandemic. 2021 , 84, 583-584	
224	Capítulo 5. Artritis inflamatorias y autoinmunes. 2021 , 28, 25-33	
223	Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial. 2021 , 43, 1214-1221	0
222	Pharmacotherapy in Systemic Rheumatic Diseases. 2021 , 83-104	0
221	Characterization of Occult Hepatitis B Virus Infection Among Iranian Patients with Behcet's Disease; Correlation with Clinical Status. 2021 , 21,	1
220	Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity. 2021 , 31, 1094-1099	0
219	Evaluation of Liver Function and Lipid profiles in Iraqi patients with Rheumatoid Arthritis. 2021 , 1853, 012040	
218	Prevalence of liver fibrosis by Fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis. 2021 , 40, 3605-3613	3
217	Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure. 2021 , 8, 775-791	1
216	Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis. <i>Scientific Reports</i> , 2021 , 11, 9184	4.9 5
215	Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis. 2021 , 17, 41-57	0
214	Association of Rheumatoid Arthritis with Diabetic Comorbidity: Correlating Accelerated Insulin Resistance to Inflammatory Responses in Patients. 2021 , 14, 809-820	2
213	Relationship between different anti-rheumatic drug therapies and complementary and alternative medicine in patients with rheumatoid arthritis: an interview based cross-sectional study. 2021 , 29, 462-466	0
212	Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors. 2021 , 8, 71-78	0

211	ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. 2021 , 116, 878-898	31
210	Environmental and health impacts of contaminants of emerging concerns: Recent treatment challenges and approaches.. 2021 , 272, 129492	35
209	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2021 , 73, 924-939	60
208	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2021 , 73, 1108-1123	62
207	Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study. 2021 , 96, 107755	14
206	Perceptions and Challenges Experienced by African Physicians When Prescribing Methotrexate for Rheumatic Disease: An Exploratory Study. 2021 , 3, 522-530	0
205	Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends. 2021 , 169, 105618	7
204	Periodontal and dental health in inflammatory bowel diseases: a systematic review. 2021 , 1-15	0
203	Molecular remission at T cell level in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2021 , 11, 166949	0
202	Avascular necrosis of the first metatarsal head in a young female adult: A case report and review of literature. 2021 , 9, 7445-7452	0
201	Methotrexate Safety in Psoriasis: An Overview. 2021 , 76, 254-267	
200	Mutual-reinforcing sonodynamic therapy against Rheumatoid Arthritis based on sparfloxacin sonosensitizer doped concave-cubic rhodium nanozyme. 2021 , 276, 121063	8
199	Association of Serum Biomarkers With Pulmonary Involvement of Rheumatoid Arthritis Interstitial Lung Disease: From KORAIL Cohort Baseline Data. 2021 , 28, 234-241	1
198	Bone formation recovery with gold nanoparticle-induced M2 macrophage polarization in mice. 2021 , 38, 102457	1
197	Temporomandibular Joint Arthritis: Implications, Diagnosis, and Management. 311-325	0
196	Interstitial Lung Disease in Connective Tissue Diseases Other Than Systemic Sclerosis. 2015 , 391-418	2
195	Risk Factors and Biomarkers of RA-ILD. 2018 , 59-72	3
194	Leveraging the electronic health record to improve quality and safety in rheumatology. 2017 , 37, 1603-1610	12

193	A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis. 2009 , 19, 384-9	4
192	Comparison of low-field dedicated extremity magnetic resonance imaging with articular ultrasonography in patients with rheumatoid arthritis. 2010 , 20, 556-60	11
191	Efficacy and safety of single-dose mizoribine for patients with rheumatoid arthritis: results at 6 months after switching from a multiple-dose regimen without a change in total daily dose. 2011 , 21, 158-63	3
190	Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients. 2011 , 21, 375-80	7
189	The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. 2011 , 21, 444-8	4
188	Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. 2011 , 21, 469-75	38
187	Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. 2011 , 21, 621-7	38
186	A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B. 2011 , 21, 701-5	11
185	Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate. 2012 , 22, 100-8	2
184	Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. 2012 , 22, 209-15	5
183	Satisfaction and attitudes toward therapy in patients with rheumatoid arthritis. 2012 , 22, 376-81	4
182	Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. 2012 , 22, 844-8	7
181	Association of hepatitis B with antirheumatic drugs: a case-control study. 2013 , 23, 694-704	12
180	Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. 2013 , 23, 430-9	21
179	Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. 2021 , 21, 9-27	15
178	Methotrexate. 2011 , 509-517.e3	2
177	Multidisciplinary approach to rheumatoid arthritis. 2011 , 965-971.e1	2
176	Methotrexate. 2015 , 443-450	3

175	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. 2013 , 917-940.e6	2
174	Treatment of Rheumatoid Arthritis. 2013 , 1137-1160.e4	2
173	Rheumatoid Arthritis. 2012 , 456-463.e1	1
172	Disease modifying drugs for rheumatological diseases: a brief history of everything. 2020 , 120, 313-348	2
171	Quality assessment of websites providing educational content for patients with rheumatoid arthritis. 2017 , 46, 715-723	13
170	Spinal and paraspinal inflammatory reactions after epidural steroid injection in a patient taking disease-modifying antirheumatic drugs. 2021 , 46, 358-361	1
169	Denosumab and the treatment of rheumatoid arthritis: In an occupied field, where will a RANKL inhibitor fit in?. 2008 , 5, 351-356	1
168	In vivo imaging of early stages of rheumatoid arthritis by $\alpha_4\beta_1$ -integrin-targeted positron emission tomography. 2019 , 9, 87	10
167	An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. 2009 , 4, e7556	81
166	Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. 2012 , 7, e47373	25
165	Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation--an economic analysis based on the ESPOIR cohort. 2014 , 9, e97077	17
164	Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. 2015 , 10, e0120749	21
163	[Immunologic changes in diffuse large B-cell lymphomas after rituximab-CHOP treatment: own data and review of the literature]. 2012 , 153, 1658-66	1
162	Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach. 2020 , 78, 430-439	3
161	Biologics for rheumatoid arthritis: an overview of Cochrane reviews. 2010 , 128, 309-10	47
160	Have the annual trends of total hip arthroplasty in rheumatoid arthritis patients decreased?. 2017 , 5, S35	6
159	A Pilot Study to Evaluate the Effects of Oral N-Acetyl Cysteine on Inflammatory and Oxidative Stress Biomarkers in Rheumatoid Arthritis. 2019 , 15, 246-253	9
158	Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. 2013 , 7, 119-24	69

157	Personalized medicine for the vasculitis patient: hope for the future?. 2009 , 4, 127-132	1
156	[Biologic therapy of rheumatoid arthritis]. 2009 , 137, 205-10	3
155	A Systematic Review to Identify the Effects of Biologics in the Feet of Patients with Rheumatoid Arthritis. 2020 , 57,	2
154	Current trends in management of hepatitis B virus reactivation in the biologic therapy era. 2011 , 17, 3881-7	47
153	Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. 2015 , 21, 10274-89	63
152	Strategies for the management of rheumatoid arthritis. 2012 , 35, 125-30	13
151	Perioperative Management of Rheumatoid Medications in Orthopedic Surgery. 2017 , 40, 282-286	3
150	Patient-related medical risk factors for periprosthetic joint infection of the hip and knee. 2015 , 3, 233	33
149	A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. 2011 , 2011, 815038	74
148	Pleuropulmonary manifestation in patients with rheumatoid arthritis in Saudi Arabia. 2017 , 12, 266-271	7
147	Personalized medicine in rheumatoid arthritis: rationale and clinical evidence. 2012 , 2, 797-802	2
146	Epidemiological evaluation quality of life in patients suffering from early rheumatoid arthritis: a pragmatic, prospective, randomized, blind allocation controlled of a modular program group intervention. 2015 , 37, e2015048	3
145	Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. 2015 , 7, 2716-28	4
144	Severe methotrexate toxicity after treatment for ectopic pregnancy: A case report. 2016 , 13, 221-223	4
143	Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms. 2020 , 58, 390-400	2
142	Rheumatoid factor mediates excess serum lipoprotein(a) for independent association with type 2 diabetes in men. 2015 , 15, 782-8	2
141	Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study). 2015 , 2, 149-154	2
140	Perioperative management of the patient with rheumatoid arthritis. 2014 , 5, 283-91	39

- 139 The effect of leflunomide on cold and vibratory sensation in patients with rheumatoid arthritis. **2012**, 36, 207-12 2
- 138 Arthroscopic Management of Inflammatory Arthritis Affecting the Elbow. **2021**, 583-598
- 137 Synergistic Effects of BTK Inhibitor HM71224 and Methotrexate in a Collagen-induced Arthritis Rat Model. **2021**, 35, 3245-3251
- 136 ??????. **2009**, 55, 153-157
- 135 New and upcoming biologic agents for rheumatoid arthritis. **2010**, 33, 30-4
- 134 Rheumatoid Arthritis. **2010**, 823-828
- 133 Recent Trend in the Treatment of Rheumatoid Arthritis. **2010**, 45, 419 4
- 132 Is er evidentie dat methotrexaat in de dosering, zoals gebruikt bij reumatoïde artritis, de nierfunctie kan doen verslechteren?. **2010**, 50-55
- 131 Artritis reumatoïde. **2010**, 117-162
- 130 BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. **2010**, 0
- 129 Progress in the Treatment of Rheumatoid Arthritis and Decreasing Number of Patients Participating in Clinical Trials. **2011**, 42, 401-407
- 128 The Complex Management of Viral-Related Autoimmune Diseases. **2011**, 345-357
- 127 Rheumatologic aspects of viral infections. **2011**, 1087-1092
- 126 Management of rheumatoid arthritis. **2011**, 955-963.e2
- 125 C15 Disease-modifying antirheumatic drugs. **2011**, 585-619
- 124 An Overview. **2011**, 125-137
- 123 Drug Therapy for Interstitial Lung Disease. **2012**, 101-120
- 122 Usefulness of ultrasonographic assessments for the detection of rheumatoid arthritis (RA) during health evaluation and promotion. **2012**, 39, 545-548

121 Perfil de seguridad y monitorización de los fármacos anti-TNF en la uveítis. **2012**, 83-90

120 Rheumatoid Arthritis. **2012**, 1-26

119 Rheumatoid Arthritis of the Knee. **2012**, 734-737

118 Prevention and Treatment of Medical Complications. 484-494

117 Applying Item Response Theory Methods to Improve the Measurement of Fatigue in a Clinical Trial of Rheumatoid Arthritis Patients Treated with Secukinumab*. **2013**, 03, 192-201

116 Cytological examination of synovial fluid assessed in the diagnosis of rheumatoid arthritis and other related joint diseases. **2013**, 52, 287-294

1

115 The Present State and Future Direction of Rehabilitation Medicine in the Treatment of Rheumatoid Arthritis. **2013**, 50, 547-551

114 DYNAMICS OF CARDIOVASCULAR STATUS AND SERUM MARKERS OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS, TREATED WITH INFlixIMAB. **2013**, 12, 80-84

113 The Geoepidemiology of Autoimmune Liver Disease. **2014**, 27-43

112 Respiratory Infections in the Rheumatic Disease Patient. **2014**, 167-177

111 Findings of ^{18}F -Fluorodeoxyglucose Positron-Emission Tomography in Methotrexate-Related Lymphoproliferative Disorder. **2014**, 04, 293-300

110 Chapter 26. Rheumatoid Arthritis, Osteoarthritis, Gout, and Lupus. **2015**,

109 Wound Issues after Total Knee Arthroplasty. **2015**, 5, 10-13

108 Multidisciplinary approach to rheumatoid arthritis. **2015**, 809-814

2

107 Rheumatologic aspects of viral infections. **2015**, 912-917

106 Immunotherapy. **2015**, 195-232

105 Rational Usage of Disease Modifying Anti-Rheumatic Drugs with the Guidance of EULAR and ACR Suggestions. **2015**, 05, 104-112

104 Genomics/Proteomics of NEXT-II α , a Novel Water-Soluble, Undenatured Type II Collagen in Joint Health Care. 338-345

103 Autoimmune and Connective Tissue Diseases. 201-229

102 Overview of Biologic Therapies. **2016**, 29-38

101 Perioperative Optimization. **2016**, 305-315

100 Pharmacotherapy of Rheumatoid Arthritis. **2016**, 19-37

99 Late Infections: Algorithm Approach. **2016**, 189-200

98 An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. **2016**, 22, 1092-1106

97 Rheumatoid Arthritis. **2017**,

96 Chapter 26: Arthritis. **2017**,

95 THE ROLE OF LABORATORY BIOMARKERS IN MONITORING THE EFFECTIVENESS OF TREATMENT WITH INHIBITORS OF TUMOR NECROSIS FACTOR IN RHEUMATOID ARTHRITIS. **2018**, 66, 32-34

94 Vaccination for Patients with Rheumatic Diseases in the Era of Biologics. **2018**, 25, 100

2

93 Hepatitis B and hepatitis C infection prevalence in ankylosing spondylitis patients. **2018**, 10, 297-301

92 The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis. **2018**, 12, 120-123

91 Planning of a Clinical Data Registry for Basic Anti-Inflammatory Drugs for the Treatment of Rheumatoid Arthritis. **2018**, 8, 238-245

1

90 Disease-Modifying Anti-rheumatic Drugs. **2019**, 709-750

89 Perioperative outcomes associated with thoracolumbar 3-column osteotomies for adult spinal deformity patients with rheumatoid arthritis. **2019**, 30, 822-832

4

88 The Risk of Cardiovascular Disease and Diabetes in Rheumatoid Arthritis Patients: A Propensity Score Analysis. **2019**, 29, 109-114

1

87 A 42-Year-Old Woman with Progressive Limb Weakness and Breathing Difficulty. **2020**, 221-227

86 Pancytopenia as a Complication of Low-Dose Methotrexate in a Septuagenarian: A Rare Presentation. **2020**, 12, e8492

0

- 85 Noninvasive assessment of liver fibrosis in Crohn's disease patients exposed to methotrexate. **2021**, 33, 794-798 1
- 84 Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. **2021**,
- 83 Design of clinical development programs. **2022**, 653-679
- 82 Manejo de intercorrências durante o uso dos imunobiológicos: infecções, gestação e neoplasias. **2017**, 19-25
- 81 Manejo pré-operatório dos agentes imunobiológicos em pacientes reumatológicos. **2017**, 26-30
- 80 Rituximab in dermatology: Revisited. **2020**, 6, 5
- 79 Identifying Risk Factors Associated With Postoperative Infection Following Elective Lower-Extremity Total Joint Arthroplasty. **2020**, 24, 1-3 1
- 78 Nanoscience: Convergence with Biomedical and Biological Applications. **2020**, 1-25 0
- 77 Hydroxychloroquine (HCQ): an observational cohort study in primary and secondary prevention of pneumonia in an at-risk population. 1
- 76 Cost minimization analysis of mainstay treatments in cutaneous lupus erythematosus. **2021**, e15190 0
- 75 Development of pancytopenia after single low-dose methotrexate therapy in patients with chronic kidney disease: a review of the literature. **2020**, 2, 83-90 0
- 74 Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. **2009**, 19, 513-21
- 73 Anti-tumor necrosis factor therapy in rheumatoid arthritis patients with a history of deep prosthetic joint infection: a report of four cases. **2011**, 21, 542-7
- 72 Induction of clinical remission with adalimumab-methotrexate combination therapy in a patient with rheumatoid arthritis and concomitant hepatitis C virus infection. **2011**, 21, 696-700 1
- 71 Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice. **2013**, 23, 466-77 6
- 70 Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. **2013**, 23, 709-15 5
- 69 Tuberculous pleurisy diagnosed by medical thoracoscopy in an adalimumab-treated rheumatoid arthritis patient after treatment of latent tuberculosis infection. **2013**, 23, 1013-7 1
- 68 Does Immunodeficiency Matter in ENT?. **2021**, 457-469

67	A rich pipeline that needs to be managed. 2009 , 6, 35-40	1
66	A Human Monoclonal Antibody Against Tumor Necrosis Factor-alpha. 2009 , 34, 2-30	
65	Hepatitis C-related arthropathy: Diagnostic and treatment considerations. 2010 , 27, 351-354	12
64	Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?. 2013 , 124, 174-90	56
63	Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid Arthritis. 2013 , 6, 126-36	2
62	Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers. 2012 , 5, 83-92	9
61	Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study. 2010 , 3, 266-73	3
60	Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis. 2014 , 32, 324-32	10
59	Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis. 2015 , 8, 494-505	3
58	Using LASSO Regression to Predict Rheumatoid Arthritis Treatment Efficacy. 2016 , 2016, 176-83	6
57	Inhibition of microRNA-21 decreases the invasiveness of fibroblast-like synoviocytes in rheumatoid arthritis via TGF β /Smads signaling pathway. 2016 , 19, 787-93	12
56	Study of the Effect of an Oral Formulation of Fig and Olive on Rheumatoid Arthritis (RA) Remission Indicators: A Randomized Clinical Trial. 2016 , 15, 537-545	8
55	Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis. 2017 , 10, 7-15	8
54	Risk of tuberculosis reactivation with rituximab therapy. 2017 , 11, 41-44	10
53	Severe Harm and Death Associated With Errors and Drug Interactions Involving Low-Dose Methotrexate. 2018 , 43, 191-248	2
52	Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy. 2018 , 11, 192-202	6
51	Insights and Implications of the VA Rheumatoid Arthritis Registry. 2015 , 32, 24-29	11
50	Preoperative Evaluation and Management of Patients Receiving Biologic Therapies. 2019 , 7, 220-228	1

- 49 [Efficacy of internalized RGD-modified echogenic liposomes in diagnosis and treatment in a mouse model of rheumatoid arthritis]. **2017**, 37, 1283-1289
- 48 Methotrexate-Related Liver Cirrhosis in Psoriatic Arthritis: A Case Report and Review of the Literature.. **2021**, 32, 264-272 2
- 47 Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis. **2021**, 359 0
- 46 Patient Perceptions and Preferences Regarding Telemedicine for Rheumatologic Care during the COVID-19 Pandemic.. **2022**, 1
- 45 Hepatitis B and C virus reactivations under biologic treatments in patients with rheumatic diseases: long-term results from a single-center.
- 44 Phytochemicals targeting JAK/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?. **2022**, 197, 114929 1
- 43 Short-term induction glucocorticoids and disease-modifying anti-rheumatic drugs (DMARD) therapy for rheumatoid arthritis. **2021**, 2021, 2
- 42 Rheumatoid arthritis: immunogenetic factors and immune therapies. **2022**, 279-307
- 41 Homeopathy as a Therapeutic Option in Space. **2022**, 955-965
- 40 Juvenile Idiopathic Arthritis-associated Uveitis: Diagnosis, Management, Sequelae.. **2022**, 62, 143-154
- 39 Appropriate use criteria for endotracheal suction interventions in mechanically ventilated children: The RAND/UCLA development process.. **2021**,
- 38 Novel treatment for refractory rheumatoid arthritis with total glucosides of paeony and nobiletin codelivered in a self-nanoemulsifying drug delivery system. **2021**, 0
- 37 Homeopathy as a Therapeutic Option in Space. **2022**, 1-11
- 36 Diseases of joints. 313-344
- 35 A randomised clinical trial to assess the adjuvant potential of methotrexate to corticosteroids in mucosal or limited mucocutaneous pemphigus vulgaris.. *Scientific Reports*, **2022**, 12, 7525 4.9
- 34 Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. *Frontiers in Medicine*, **2022**, 9, 4.9 3
- 33 Plasma angiotensin peptides as biomarkers of rheumatoid arthritis are correlated with anti-ACE2 auto-antibodies level and disease intensity. *Inflammopharmacology*, 5.1
- 32 Consensus on a standardised treatment pathway algorithm for lumbar spinal stenosis: an international Delphi study. *BMC Musculoskeletal Disorders*, **2022**, 23, 2.8 0

31	Treatment Guidelines in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2022 ,	2.4	1
30	Singapore Chapter of Rheumatologists Consensus Statement on the Eligibility for Government Subsidy of Biologic Disease Modifying Antirheumatic Agents for Treatment of Rheumatoid Arthritis (RA). <i>Annals of the Academy of Medicine, Singapore</i> , 2014 , 43, 400-411	2.8	3
29	Renal sarcoidosis. <i>Nephrology Dialysis Transplantation</i> ,	4.3	
28	Therapeutics in rheumatology and the kidney.		
27	AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.		1
26	Associations between shortened telomeres and rheumatoid arthritis-associated interstitial lung disease among U.S. Veterans. 2022 , 201, 106943		0
25	Potential of Disease-Modifying Anti-Rheumatic Drugs to Limit Abdominal Aortic Aneurysm Growth. 2022 , 10, 2409		0
24	Overview of Methotrexate Toxicity: A Comprehensive Literature Review. 2022 ,		0
23	Off-Label Uses of Rituximab in Dermatology.		1
22	Physicians' Agreement on and Implementation of the 2019 European Alliance of Associations for Rheumatology Vaccination Guideline: An International Survey. 2022 ,		1
21	Physicians' perspective on vaccination in patients with autoimmune inflammatory rheumatic diseases: an international survey. <i>jrheum</i> .220135		1
20	A Sub-pixel Accurate Quantification of Joint Space Narrowing Progression in Rheumatoid Arthritis. 2022 , 1-14		0
19	Predicting hepatotoxicity associated with low-dose methotrexate using machine learning.		0
18	Infections Related to Biologic Response Modifying Drug Therapy. 2023 , 674-678.e3		0
17	Examining the safety of relaxed drug monitoring for methotrexate in response to the COVID-19 pandemic. 2022 , 6,		0
16	Correlation of rheumatoid and cardiac biomarkers with cardiac anatomy and function in rheumatoid arthritis patients without clinically overt cardiovascular diseases: A cross-sectional study. 2023 , 44, 101161		0
15	Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices. 12,		1
14	Trends in Total Joint Arthroplasty Among Patients With Rheumatoid Arthritis: The Effect of Recent Disease Modifying Antirheumatic Drug Utilization Guidelines. 2022 , 6,		0

- 13 Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematosus. ○
- 12 Core Constituents of Caragana sinica Root for Rheumatoid Arthritis Treatment and the Potential Mechanism. **2023**, 8, 2586-2595 ○
- 11 A survey on the clinical practice of rheumatoid arthritis management by Korean medicine doctors. **2023**, 58, 102227 ○
- 10 Joint space narrowing progression quantification with joint angle correction in rheumatoid arthritis. **2022**, ○
- 9 Comparative efficacy and safety of JAK inhibitors and leflunomide in rheumatoid arthritis: A protocol for systematic review and meta-analysis. **2022**, 101, e32154 ○
- 8 Acute diverticulitis in immunocompromised patients: evidence from an international multicenter observational registry (Web-based International Register of Emergency Surgery and Trauma, Wires-T). ○
- 7 Perioperative treatment with TNF inhibitors does not affect survival of total hip arthroplasty in inflammatory arthritis: A registry-based cohort study. **2023**, 60, 152201 ○
- 6 Muscadine grape (vitis rotundifolia) and wine polyphenols alleviated arthritis and restored the gut microbial composition in mice. **2023**, 116, 109311 ○
- 5 Perioperative Medication Management in Elective Plastic Surgery Procedures. Publish Ahead of Print, ○
- 4 Predicting Hepatotoxicity Associated with Low-Dose Methotrexate Using Machine Learning. **2023**, 12, 1599 ○
- 3 Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARD), targeted synthetic DMARD (tsDMARD) and biosimilar DMARD (bsDMARD) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity. ○
- 2 Differentiation of Rheumatoid Arthritis From HCV Infection: Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide or Anti-Mutated Citrullinated Vimentin?. **2010**, 25, 19-23 ○
- 1 Microbiome: Impact of sex on function and characteristics of gut microbiome. **2023**, 313-329 ○